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With the rapidly increasing use of proteins as biotherapeutics to treat diseases, the 
characterization of these large molecules using mass spectrometry has become a highly attractive 
field of research. A particular area of research is the identification and characterization of protein 
post-translational modifications.  Disulfide bonds and glycosylation are among the most critical 
protein post-translational modifications (PTMs), as they play vital roles in maintaining the 
proper protein folding, structure, and functions. These two PTMs are particularly important in 
the development and characterization of monoclonal antibody-based drugs, which are the most 
prevalent protein therapeutics in the market.  Among the four classes of immunoglobulins 
(IgG’s), the disulfide connectivity of IgG1, IgG2 and IgG4 have been effectively studied, and 
IgG2 and IgG4 have been shown to have disulfide bond-mediated isomers due to alternative 
disulfide bond connectivity. However, no studies to investigate the presence of disulfide related 
isomers in IgG3 have been done. In this dissertation, high resolution mass spectrometry is used 
map the disulfide bond connectivity in IgG3 in order to investigate the presence of disulfide-
mediated isomers. The results indicate that no such isomers exist for endogenous IgG3 
antibodies.  
The development of a novel glycoproteomics software, Glycopep Decoy Generator (Tool 
1), and the generation of a large dataset of manually assigned CID spectra (Tool 2) from diverse 
glycopeptide compositions also are described herein. The decoy generator generates abundant 
decoys for any target glycopeptide composition, and when it is used along with the dataset of 
CID spectra, the accuracy of glycopeptide scoring algorithms can be readily determined. The 
tools were used to assess GlycoPep Grader, a scoring algorithm that assigns glycopeptides to 
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CID spectra. The results indicate that GlycoPep Grader has some weaknesses in scoring spectra 
from fucosylated glycopeptide compositions. These weaknesses could not be easily identified 
without the aforementioned tools. In order to address GlycoPep Grader’s limitations, a thorough 
investigation of the root cause of its weaknesses is carried out, and potential updates that could 
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Chapter 1: Introduction 
 
1.1 Protein Disulfide Bonds 
1.1.1 Formation and Importance 
Disulfide bonds are post-translational modifications in proteins formed between the 
sulfur atoms of two cysteine (Cys) residues during the biosynthesis of the proteins in the cell. 
The formation of the covalent bond results from oxidation of the free thiol (-SH) side chains of 
the Cys residues, primarily catalyzed by enzymes, including protein disulfide isomerase (PDI) 
and endoplasmic reticulum oxidoreductin 1protein (Ero1p).
1,2 
A significant number of proteins 
contain disulfide bonds. Based on the known tertiary structures of 817 plasma proteins that 
contain 4594 disulfide bonds, Butera et al 
3
 approximated the ratio of protein-to-disulfide bond at 
1:5. Hence, the approximately 2000 plasma proteins identified by Farrah et al 
4
 would contain 
about 10,000 disulfide bonds, representing an enormous number of disulfide bonds in plasma 
proteins, alone. Disulfide bonds are important in protein folding, and they have both structural 
and functional roles in the proteins.  
Structurally, disulfide bonds ensure proper folding of proteins, can lead to structural 
isoforms,
5
 and they stabilize the native high-order conformations of the proteins that are 
necessary to execute their biological functions.
6,7
 The concept of disulfide engineering is, 
therefore, an attractive choice in biotechnology as non-native disulfide bonds can be engineered 
into proteins to increase the protein stability. For instance, some proteins that initially lacked 
disulfide bonds have been shown to be more stable with engineered disulfides,
8,9
 and the stability 










 and decreased immunogenicity.
16
 Besides proteins, peptides with engineered 
disulfide bonds have also shown increased stability and half-life.
17,18
 Although the above 
examples demonstrate the benefits of additional disulfide bonds in proteins and peptides, not all 
engineered disulfide bonds produce the expected increase in protein stability.
19
  
Some disulfide bonds, known as allosteric disulfides, are responsible for effective 
biological functions of proteins, and the cleavage of such bonds would lead to a change in the 
protein activity.
20
 The functional roles of allosteric disulfide bonds in blood and cancer cells 
have been extensively reviewed by Hogg et al.
3,21
  A recent report showed that reduction and 
alkylation of some disulfide bonds in rituximab and trastuzumab, IgG1-based drugs, increased 
the binding affinity of the modified drug to some Fc gamma receptor isotypes,
22,23
 but also led to 
decreased binding to other Fc gamma receptors.
23
 In some cases, mutation of Cys residues 
involved in disulfide bonds may have no effect on the protein’s biological activity, as is the case 
of an IgG2 antibody where Cys to Ser mutations led to structural changes but had no impact on 
the binding of the protein to receptors and to complement C1.
24
  
Mapping the disulfide connectivity pattern in proteins, therefore, provides important 
information for research pertaining to protein stability, structure-function relationships, and any 
disulfide-mediated isoforms of proteins. In addition, disulfide bond characterization is of high 
importance during the development of biopharmaceuticals to ensure the safety and potency of 
biologics, which have increased dramatically in the drug market in recent years. Hence, there is 
an increasing demand for efficient analytical methods for accurate characterization of disulfide 
bonds in proteins, particularly therapeutic proteins. 
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1.1.2 Disulfide Bonds in Biotherapeutics 
Protein disulfide bond characterization has become even more important in 
biopharmaceutical industries, due to the increasing use of recombinant proteins as 
biotherapeutics (biologics) for the treatment of diseases such as cancer, arthritis, asthma, and 
diabetes;
25,26
 and as vaccines against various diseases.
27,28
 These biologics are from a vast array 




 and growth factors.
31,32
 
All these classes of biomolecules contain proteins that are disulfide bonded. Among these 
proteins, immunoglobulin gamma (IgG) antibodies are highly disulfide bonded (between 16 to 
25 disulfide bonds, depending on the type of IgG),
33
 and IgG-based therapeutics are the most 
prevalent in the market. As such, disulfide bonds are one of the many critical quality attributes 
(CAQs) of antibody-based drugs that have to be monitored throughout their development stages, 





 The presence of free Cys (reduced disulfide bonds) have been 
reported during manufacturing, and they can lead to formation of non-native disulfide bonds and 
aggregates,
38,39
 and possibly cause immunogenicity and loss of biological activity of the 
biotherapeutics. Hence, disulfide bond characterization is necessary during biologic development 
to confirm the correct disulfide connectivity and to verify the presence, or absence, of disulfide 
bond variants in order to ensure the safety and efficacy of the drugs. In addition, regulatory 
agencies require comprehensive characterization of the disulfide bond pattern in biomolecules, in 
order to meet the quality-by-design (QbD) requirements for biologics,
40,41
 hence the need for 
effective methods to map disulfide bonds in biotherapeutics.  
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1.2 Analytical Methods for Disulfide Bond Characterization 
Several methods for disulfide bond analysis in proteins have been developed using a 









 and liquid chromatography coupled to mass 
spectrometry (LC-MS),
49-51
 which is the focus of this review. NMR and X-ray crystallography 
provide information about disulfide bonds at the molecular level, but they require large amounts 
of highly pure samples, and they are not typically used for disulfide bond mapping. Traditional 
methods, such as Edman degradation and diagonal paper electrophoresis, were the prominent 
methods for disulfide bond mapping in the early 1960s, although Edman degradation methods (in 
combination with mass spectrometry) were still sparingly used in the late 2000s.
5,46
 With the 
advent of mass spectrometry, LC-MS and tandem mass spectrometry (LC-MS/MS) methods 
have become the go-to methods for disulfide bond mapping in proteins.  
Bottom-up mass spectrometry is the most widely used method for disulfide bond analysis 
in proteins. The attractive aspects of the bottom-up approach include the availability of a variety 
of enzymes to digest the large biomolecules into small pieces (peptides containing intact 
disulfide bonds) that are easier to analyze, several soft ionization techniques, complementary 
fragmentation techniques, and the ability to couple mass spectrometers with LC systems for 
separation of the enzymatic digests prior to MS analysis. Despite the wide use of mass 
spectrometry for disulfide bond analysis, disulfide bond characterization is still a challenging 
task, especially for proteins with high Cys content and complex disulfide connectivity, and for 
determination of low levels of disulfide bond scrambling. Hence, numerous methods for 
disulfide bond analysis have been developed, in part, to address these challenges. 
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In the following sections, we review the recent bottom-up mass spectrometric methods 
for disulfide bond analysis and provide important considerations for the steps involved. A 
number of reviews for disulfide bond analysis containing additional methods that were 
developed prior to 2007 have been reported.
49-51
 Herein, we begin by taking an in-depth look at 
sample preparation, which is a key step in the successful mapping of native and alternative 
disulfide bonds in proteins. We provide several important tips to prevent the introduction of 
disulfide artifacts (or scrambling) during sample preparation. Finally, we discuss the 
fragmentation characteristics of disulfide-linked peptides upon subjection to various mass 
spectrometric dissociation techniques that are important for disulfide bond mapping and describe 
recent MS-based disulfide bond characterization methods that have been developed within the 
past decade. Researchers involved in method development for protein characterization can use 
the information herein to facilitate development of new MS-based methods for protein disulfide 
bond analysis. In addition, individuals doing biotherapeutics characterization, especially 
disulfide bond mapping in antibodies, can use this review article to choose best strategies for 
disulfide bond assignment of their biologic products. 
1.3 Sample Preparation for Bottom-up Mass Spectrometric Disulfide Bond Analysis  
1.3.1 Overview of Sample Preparation Methods  
Sample preparation is a critical step in bottom-up mass spectrometric disulfide bond 
analysis.  In general, the analysis is usually done using one of two ways: non-reduced (intact) 
analysis or reduced/intact analysis. The sample preparation workflow for the non-reduced 
approach, which is the most commonly used method, is shown in Figure 1. This approach 
requires proteolytic digestion of the protein without disulfide bond reduction, and the disulfide 
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linked peptides are investigated to decipher the disulfide connectivity in the protein.
52-54
 For the 
intact/reduced approach, two batches of enzymatically digested samples are prepared, one with 
the disulfide bonds intact (same as the previous approach) and the other with reduced disulfide 
bonds. The disulfide connectivity of the protein is determined by comparing the peptide map 
profiles (LC profiles) of the two sample batches.
55,56
 The disulfide bond analysis methods which 




Figure 1. Disulfide bond analysis workflow. (A.) Sample preparation of non-reduced protein digest for 
disulfide bond analysis of a glycoprotein. (B.) Disulfide bond assignment from LC-MS/MS data. Note: 
deglycosylation is not necessary is the protein is not glycosylated. 
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1.3.2 Preventing Disulfide Bond Artifacts during Sample Preparation 
A major requirement during sample preparation is to prevent the formation of non-native 
disulfide bonds (disulfide bond artifacts). To this end, a number of methods aimed at efficiently 
mapping disulfides in proteins without the formation of disulfide artifacts during sample 
preparation have been recently reported.
57,58
 Disulfide bond artifacts can be induced during 
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 where disulfide scrambling usually occurs, especially for proteins 
containing free thiols. Besides pH and temperature, the thiol size, disulfide size, and the steric 
effects (exposure) of the thiols can also affect the formation of scrambled disulfide bonds, as 
shown by Kerr and coworkers
64
; but these factors cannot be controlled during sample 
preparation. 
Temperature, pH, and the availability of free Cys are, therefore, the critical factors that 
must be controlled during sample preparation in order to prevent the formation of non-native 
disulfide bonds. Generally, samples for disulfide bond analysis are prepared at room temperature 
and then subjected to enzymatic digestion at 37°C, and such low temperatures do not trigger any 
cysteine reaction or disulfide bond shuffling.
63
 However, pH tremendously affects disulfide bond 
or cysteine reactivity, even at room temperature, and must be carefully controlled during sample 
preparation.
63,64
 Sample preparation should be done at slightly acidic pH because at alkaline pH, 
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free thiols are deprotonated, and the resulting thiolate anions are oxidized or react with adjacent 
disulfide bonds (thiol/disulfide exchange) to form new, non-native disulfide bonds. The thiol 
groups that are more exposed to solvent will be more reactive than those that are not exposed.
64
  
Therefore, the first step during sample preparation for disulfide analysis is to cap any free 
cysteine residues in order to prevent formation of non-native disulfide bonds. This step is 
important even for proteins for which all the Cys residues are known to be in the disulfide 
bonded state because low levels of free Cys residues could be present. For example, although all 
the Cys residues in the four classes of IgG are expected to be disulfide bonded, low levels of free 
Cys residues have been detected in all 4 IgG classes,
33
 and the free Cys residues can induce 
disulfide artifacts if they are not alkylated or not properly alkylated. Commonly used Cys 
alkylating reagents include: iodoacetamide (IAM), iodoacetic acid (IAA), and N-ethyl-
maleimide (NEM).
67,68
 Rogers and coworkers showed that NEM is a more suitable alkylating 
agent for protein thiols than IAM and IAA because it reacts faster, requires less reagent per mole 
of free Cys, and is very effective at acidic pH (pH 4.3 to 7.0),
68
 while the other reagents are most 
effective at alkaline pH (pH 8.0), where thiol/disulfide exchange and free Cys oxidation 
reactions can compete with alkylation and lead to low levels of non-native disulfide bonds. 
Recently, Lu et al 
69
 reported low levels of disulfide artifacts when disulfide bond mapping of 
RNase A was done after alkylating free thiols with IAM and IAA at pH 6.5, but no artifacts were 
identified when the experiments were done at the same pH using NEM; indicating that IAM and 






Protein digestion can be done either chemically or enzymatically.
70
 Table 1 shows 
different types of disulfide-linked peptides that can result from protein digestion. Enzymatic 
digestion is the most widely used protein digestion approach, and there are a variety of enzymes 
to choose from, as reviewed by Switzer et al.
70
 Selecting an appropriate enzyme for effective 
digestion is important because the enzyme used would determine the types of disulfide bonded 
peptides in the protein digest (Table 1).  In selecting an enzyme, the goal is usually to choose one 
that produces more “simple” inter-chain disulfide-linked peptides, preferably with only one 
interchain disulfide bond and with bonded chains of appropriate lengths (4-15 AA residues). 
Such dipeptides can be easily mapped manually and with existing analysis software. For this 
purpose, in silico digestion of the protein using different enzymes is needed to select the best 
enzyme. Two important questions that can help in selecting a suitable enzyme are: (1) what are 
the sizes (number of disulfide bonded peptide chains and the length of each chain) of the 
disulfide linked peptides? and (2) How complex are the disulfide connectivity of the disulfide-
linked peptides? That is, are there only interchain disulfide bonds, interchain and intrachain 
disulfide bonds, nested intrachain disulfide bonds? etc. If a single enzyme does not yield 
disulfide-bonded peptides with simple interchain disulfide bonds, a combination of enzymes can 
be used.
71,72
 However, it is worth noting that using multiple enzymes could lead to very short 
disulfide-bonded peptides, which may not be retained in reverse-phase columns, making 
disulfide assignment difficult. In such cases, a planned digestion that deliberately ensures missed 
cleavages in order to obtain longer peptide chains can be done.
72
 In addition to the type of 
disulfide bonded peptides generated, another important consideration is the digestion efficiency 
10 
 
of the enzyme used. Glatter et al studied several protein digestion strategies and showed that a 
combination of trypsin and Lys-C gives better digestion efficiency than trypsin alone.
73
 
Table 1: Types of disulfide bonded peptides (DSBPs) from proteolytic digestions 
 
- Aspartic acids in green (D) represent asparagine residues that were converted to aspartic acids after 
deglycosylation with PNGase F.  





As mentioned earlier, the most important consideration (factor) during sample 
preparation for disulfide analysis is to prevent the formation of non-native disulfide bonds. 
Therefore, as with the case for alkylation, the pH and temperature are also critical during 
digestion. Proteolytic digestion is commonly done at 37°C, where no scrambling occurs. In fact, 
Wang et al recently showed that trypsin plus Lys-C digestion can also be done with high 
digestion efficiency at room temperature.
58
 Hence, pH is, again, a critical factor in preventing 
disulfide shuffling during protein digestion. Since disulfide artifacts can be introduced when  
samples are prepared at alkaline pH,
59,60
 protein digestions for disulfide bond mapping tend to be 
done at neutral or slightly acidic pH. Recently, Sung et al 
57
 investigated disulfide scrambling in 
lysozyme and bevacizumab (an IgG1 antibody drug) upon digestion with trypsin, trypsin plus 
Glu-C, and Lys-C at pH of 6 and 7; and thermolysin at pH ranging from 5 to 7. No disulfide 
scrambling was observed when digestion was done using trypsin, trypsin plus Glu-C, and Lys-C 
at pH of 6. However, disulfide scrambling was observed when digestion was done at pH 7 using 
the same enzymes, and at pH 5 to 7 using thermolysin.
57
 Similarly, low levels of disulfide 
scrambling have also been reported when trypsin or Lys-C plus trypsin were used for protein 
digestion at pH of 6.8.
71,74,58
 Nonetheless, disulfide scrambling at neutral or slightly acidic pH 
conditions may depend on a variety of conditions in addition to pH, since no scrambling was 
observed when disulfide mapping of bovine fetuin was done after trypsin  digestion in buffers at 
pH of 5.5, 6.5, and 7.
75
 In some cases, disulfide scrambling at slightly acidic pH may result from 
lack of effective alkylation of any free Cys residues prior to digestion. One useful strategy in 
determining whether or not the particular digestion conditions to be used introduce artifacts  is to 
check the sample preparation method using a standard protein whose disulfide bonding is known, 
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prior to analyzing an unknown protein; this strategy has been demonstrated previously.
75
  It is 
worth noting that trypsin and Lys-C digestion at slightly acidic pH can lead to missed cleavages 
due to incomplete digestion, as the optimal efficiency of the enzymes are at pH 8.0 and pH range 
of 8.0 to 8.8, respectively;
70
 therefore, a single set of digestion conditions is not necessarily 
optimal for every protein.   
In order to completely eliminate the possibility of disulfide scrambling, digestion can be 
done using pepsin, which efficiently digests proteins at highly acidic pH (pH <2),
71,74,76
 where 
the formation of non-native disulfides via free Cys reactivity is not possible. However, pepsin is 
less specific than trypsin or Lys-C, and it may produce very small disulfide-bonded peptides that 
would be difficult to separate and analyze. Nonetheless, the use of separate pepsin and trypsin 
(pH 6) digestions could be helpful for unambiguous assignment of disulfide bonds in cases 
where ambiguity in the disulfide bond pattern has been a problem.
76
 
1.3.4 Sample Preparation of Glycoproteins  
Disulfide bond analysis of glycoproteins may require deglycosylation prior to mass 
spectrometric analysis. In order to decide whether or not a glycoprotein needs to be 
deglycosylated, the occupied glycosylation sites of the protein must first be identified, and in 
silico digestion using an enzyme of choice (or a combination of enzymes) can be done to 
decipher whether or not the Cys-containing peptides that are disulfide-linked would contain 
occupied glycosylation sites. For some glycoproteins (e.g monoclonal antibodies) 
deglycosylation is not necessary because the disulfide-bonded peptides resulting from digestion 
using the commonly used enzymes usually do not contain a glycosylation site.
65
 However, other 
glycoproteins may contain one or more occupied glycosylation sites near cysteine residues 
13 
 
involved in a disulfide bond, and in such cases, deglycosylation must be done in order to reduce 
the complexity of the MS/MS data of the disulfide bonded peptides, because glycosylation 
cannot be simply regarded as a modification on the peptide chains.
71,75,77
 For example, trypsin 
digestion of the HIV-1 Env sequence variant, C97ZA012 gp140, which contains 25 N-linked 
glycosylation sites and 10 disulfide bonds, resulted in seven tryptic, disulfide-liked peptides that 
all contain at least one occupied glycosylation site on the disulfide-linked chains.
75
 One of the 
tryptic digests was a four chain disulfide-linked peptide with six occupied glycosylation sites. In 
cases of this complexity, deglycosylation is a necessary first step. 
Deglycosylation is typically done using peptide N-glycosidase F (PNGase F) at neutral or 
slightly acidic pH,
71,75,78
 and the reaction can extend for several days if the protein is heavily 
glycosylated.
75,78
 Hence, proper Cys alkylation must be done to prevent disulfide shuffling 
during such long incubation periods. In addition, deglycosylation converts the occupied 
asparagine residue (N) to an aspartic acid residue (D), leading to a 0.985 Da mass change, which 
must be considered when calculating the molecular masses of the deglycosylated disulfide-linked 
peptides.  
1.4 Liquid Chromatography-Mass Spectrometric Disulfide Bond Analysis of Proteins  
1.4.1 Separation of Protein Digests 
Disulfide bond mapping by liquid chromatography coupled to mass spectrometry requires 
the separation and ionization of protein digests prior to mass spectrometric analysis. The widely 
used separation technique is reverse phase liquid chromatography (RPLC) by means of columns 
packed with either C8 or C18 stationary phases and mobile phases consisting of polar (e.g water) 
and non-polar (e.g acetonitrile) solvents containing modifiers such as formic acid and 
14 
 
trifluoroacetic acid (0.01 to 0.1%, v/v).  Different types of columns can be used for peptide 
separation, including microbore (e.g 1.0 and 2.1 mm internal diameter, i.d),
54,79
 capillary (e.g 0.5 
mm i.d) 
80
 and nano columns (typically 0.075 mm i.d).
65
 The typical particle size is between 3 to 
5 µm. Columns packed with 1.7 µm particles are becoming more common in recent years, but 
they require much higher pressures for separation.  
Peptide separation is usually followed by online electrospray ionization and tandem mass 
spectrometry (ESI-MS/MS) analysis. However, in some cases where the disulfide-linked 
peptides to be analyzed are very large and in low abundance, offline LC fractionation can be 
used to collect and concentrate fractions containing the disulfide-linked peptides (and carryout 
further digestion if necessary), prior to MS/MS analysis.
5
  
1.4.2 Fragmentation Techniques for Disulfide Bond Analysis 
Collision induced dissociation (CID), a dissociation method that reacts the ion of interest 
with neutral gas molecules, and electron transfer dissociation (ETD), a dissociation method that 
reacts the ion with an electron carrier, are the most commonly used fragmentation techniques for 
mass spectrometry-based disulfide bond analysis.
54,80,81
 Figure 2 shows CID and ETD spectra of 
a simple interchain disulfide-bonded peptide from IgG3 monoclonal antibody that exhibits the 
characteristic fragment ion peaks that result from subjecting disulfide-bonded peptides to CID 
(Figure 2A) and ETD (Figure 2B)  fragmentation.  
CID typically leads to the fragmentation of the peptide backbone (amide) bonds, while 
leaving the disulfide bond intact; hence producing b and y ions that contain the disulfide bond 
(ions in red in Figure 2A), as well as ions that do not contain the disulfide bond (ions in green, 
Figure 2A).  Although assignment of CID-generated product ions of disulfide-bonded peptides 
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was previously based on the assumption that only one peptide bond is cleaved during CID, Clark 
et al 
80
 recently showed that cleavage of two peptide bonds (double cleavage) is common during 
CID fragmentation of disulfide-linked peptides. The peaks labeled in red brackets in Figure 2A 
are examples of this type of cleavage. Although  CID does not typically cleave disulfide bonds, a 
few instances have been reported where thioaldehydes, persulfides, and dehydroalanine ion 





Figure 2. CID (A) and ETD (B) spectra of a disulfide bonded peptide from the CH2 domain of IgG3 
monoclonal antibody. The spectra show the characteristic b/y (A) and c/z (B) ions resulting from the 
backbone cleavage of the peptides linked by the disulfide bond. Fragment ions not containing the 
disulfide bond are labeled in green and those containing the intact disulfide bond are labeled in red. CID 
fragment ions resulting from double cleavage and containing the intact disulfide bond are in brackets. In 
the ETD spectrum (B), intense peaks of the Cys-containing peptides linked by a disulfide bond are 
observed at m/z 250.4 and 1179.3. These peaks result from the cleavage of the disulfide bond by ETD, 
and they are not observed in (A). 
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In contrast to the product ions generated from CID of disulfide bonded peptides, cleavage 
of the disulfide bond is the primary reaction pathway during ETD fragmentation.  Backbone 
(amide) cleavage also occurs, by generation of c and z ions, although this fragmentation pathway 
generally occurs at a lesser extent.
83,84
 As a result, fragment peaks representing the disulfide-
linked peptides (e.g peaks at m/z 250.4 and 1179.3 in Figure 2B) are usually more intense in 
ETD spectra than c/z ion peaks.
53,54,83
 Peaks resulting from backbone fragmentation of the 
bonded peptides may or may not contain the intact disulfide bond (fragment ions labeled in red 
and green in Figure 2B).  
Besides CID and ETD, higher-energy collisional dissociation (HCD)
85
 and a dual 
fragmentation technique known as electron-transfer and higher-energy collision dissociation 
(EThcD)
86,87
 are newer fragmentation techniques available in some Orbitrap mass spectrometers, 
and they are gaining ground in disulfide bond analysis.
79,69,74,
 HCD has similar fragmentation 
pattern to beam-type CID,
88
 and it produces only b/y ions, while EThcD spectra exhibit product 
ions present in both ETD and CID spectra (containing b/y and c/z ions), as well as ions resulting 
from disulfide bond cleavage.
74
 In addition, ultraviolet photodissociation (UVPD) is another 
fragmentation technique that is being applied for disulfide bond analysis.
89,90
 Fragmentation of 




1.4.2.1 Considerations for Selecting Fragmentation Techniques for Disulfide Analysis 
Choosing a suitable fragmentation technique or combination of techniques for data 
acquisition is vital in facilitating disulfide bond assignments from MS/MS data. The choice of a 
fragmentation method is typically based on the complexity of the disulfide linkages, the size of 
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the disulfide bonded peptides, and, to a lesser extent, on the amino acid sequence of the bonded 
chains.  Although either CID or ETD can be used to assign simple interchain disulfide bonded 
peptides (as shown in Figure 2), a careful choice of a fragmentation method is necessary for the 
assignment of complex disulfide linkages involving either intrachain or both interchain and 
intrachain disulfide bonds, large disulfide-bonded peptides with multiple peptide chains, as well 
as very small disulfide bonded peptides.  
ETD is preferred for the fragmentation of peptides that are completely cyclized by a 
disulfide bond, as recently demonstrated by Xia and colleagues.
91
 CID fragmentation of such 
peptides would typically not reveal any backbone sequence ions, whereas ETD leads to cleavage 
of the disulfide bond and the peptide backbone, thereby revealing ions that can be used to assign 
the disulfide bond.
91




), as reported by Karger 
et al,
52
 as well as a fragmentation technique involving hydroxyl radical addition followed by CID 
fragmentation, as reported by Durand et al,
92
 can also be used to map such disulfides.  
For complex disulfide cases, such as nested disulfides and cysteine knots, neither ETD 
nor CID may be sufficient as a standalone technique to unambiguously assign the complex 
disulfide bond connectivity. In such cases, methods involving combined ETD and CID 
fragmentations would be ideal to decipher the disulfide connectivity.
71,93
 The EThcD 
fragmentation method could be promising in mapping these complex disulfides, but it has not yet 
been applied to such cases. 
In terms of size, ETD is preferable for the assignment of large disulfide-bonded peptides 
containing three or more peptides linked by interchain disulfide bonds. Such large peptides can 
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easily ionize in sufficiently high charge states for ETD analysis, since ETD requires highly 
charged ions for efficient fragmentation. Due to preferential cleavage of the disulfide bonds, 
ETD spectra of large multi-chain DSBPs are less complex, and they clearly reveal which 
peptides are directly linked to each other.
75
 However, CID spectra of such large disulfide-linked 
peptides are complex and difficult to assign (e.g because of several double cleavages), and the 
spectra do not reveal which of the peptide chains are directly bonded to each other. For example, 
Go et al 
75
 assigned a three-chain disulfide-linked peptide using both CID and ETD spectra, but 
only ETD was used to unambiguously assign a four-chain disulfide-linked peptide. The ETD 
spectra of the three-chain and the four-chain disulfide-bonded peptides clearly indicated the 
chains that were disulfide-linked to each other.
75
  
On the contrary, CID is ideal for analysis of small disulfide-bonded peptides and 
disulfide-linked peptides with peptide chains that contain several adjacent proline residues. CID 
is preferable in such cases because small disulfide bonded peptides may not ionize at high charge 
states, which are required for ETD analysis, and peptide chains containing adjacent proline 
residues fragment efficiently when  subjected to CID but not ETD fragmentation, due to the N-
Cα ring structure of proline.
94
 For example, the hinge region of IgG3 contains a small dipeptide, 
CPEPK linked to CPEPK, and SCDTPPPCPR disulfide-linked to SCDTPPPCPR and a recent 
analysis of IgG3 disulfide bonds showed that these peptide chains did not fragment well under 
ETD because of the small size (for the first disulfide-linked peptide) and several adjacent proline 
residues on the peptide chains (for both disulfide-linked peptides), but they were unambiguously 
assigned using CID data.
54
 Hence, in addition to the size of a disulfide-linked peptide, the amino 
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acid sequences of the Cys-containing peptides could also be a significant factor in selecting an 
efficient fragmentation technique for disulfide analysis.  
Given the above explanations, it is imperative for researchers to do in silico digestion of a 
protein in order to study the possible types of disulfide linked peptides (see Table 1) and to make 
a decision on which fragmentation method (or combination of methods) would be suitable for 
unambiguous mapping of the disulfide bonds in a particular protein.  In general, the collection of 
both ETD and CID data proves to be very useful, since the data sets are so complementary.
53,54
   
1.4.3 Bottom-up Methods for Disulfide Bond Analysis 
A variety of bottom-up mass spectrometric methods based on the afore-mentioned 
fragmentation techniques have been reported in recent years. Figure 3 shows a schematic 
representation of bottom-up approaches for disulfide bond analysis. The methods generally fall 
under two broad categories; disulfide bond mapping from: (1) reduced and non-reduced protein 
digests (profile comparison), and (2) only intact (non-reduced) protein digests. The second 
category can be further divided into methods that require chemical or electrochemical post-
column reduction of disulfide bonds, reduction of the disulfide bonds in the gas phase (ETD and 
EThcD fragmentations), and those that do not require any reduction (typically CID and HCD 
methods).  In the following sections, we review the bottom-up methods that have been developed 






Figure 3. Schematic representation of bottom-up approaches for disulfide bond analysis. The 
methods generally fall under two broad categories: (1) disulfide bond mapping from protein 
digests with reduced and non-reduced disulfide bonds (profile comparison), and (2) disulfide 
bond mapping from only intact (non-reduced) protein digests. Non-reduced analysis can be 
further divided into methods that involve post-column reduction of disulfide bonds, reduction of 
the disulfide bonds in the gas phase (ETD and EThcD fragmentation methods), and those that do 
not require reduction of the disulfide bonds (CID and HCD fragmentation methods). Data 
analysis after post-column reduction has not been automated yet.  
 
1.4.3.1 Profile Comparison: Reduced and Non-reduced Analysis  
Disulfide bond mapping by profile comparison is usually done using two samples: a 
protein digest without reduced disulfide bonds (non-reduced sample) and a digest with reduced 
disulfide bonds (reduced sample). The two samples are separated in two LC runs (experiments), 
and peptides that are present in the ultraviolet (UV) or total ion chromatogram (TIC) profile of 
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the non-reduced sample, but are absent in that of the reduced sample, are generally considered to 
be disulfide bonded, and MS/MS analysis can be done to assign the disulfide bonds.
55,56,77
   
Herein, we present two recent examples where complete or partial reduction of the 
disulfide bonds was used to assist in disulfide mapping.  Researchers at Genentech used the 
reduced and non-reduced peptide mapping technique to assign the disulfide bonds of an unusual 
IgG1 antibody variant that was identified after size exclusion chromatography (SEC).
95
 Results 
from several experiments suggested that the mAb variant contained an extra light chain 
connected to the IgG1 monomer via a disulfide bond.  LC-MS/MS experiments using non-
reduced and reduced digests of the variant were used to confirm the disulfide linkage site of the 
extra light chain to the correct IgG1 monomer.  In a second related example, an approach that 
deviates from the standard profile comparison method was reported by Klapoetke et al.
96
 In 
order to alleviate the need for preparing and analyzing two separate samples, these researchers 
conducted a partial reduction of the disulfide bonds and alkylated the resulting resulting free 
Cys, prior to enzymatic digestion. LC-MS/MS analysis of the mixed sample, containing partially 
reduced and non-reduced disulfide-linked peptides, was used to assign the disulfide bonds of the 
protein. The method is suitable to assign complex disulfides such as Cys knots, while simple 
disulfides can be mapped using a non-reduced sample.
96
 The challenging aspect of this approach 
is to optimize the reducing agents to obtain partial reduction, as well as optimizing the alkylating 
agent to completely alkylate the reduced species.   
Overall, a shortcoming of the techniques using disulfide reduction in the workflow is the 
need to prepare and analyze two samples, or to work out sample prep conditions that afford 
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partial reduction, thereby increasing sample preparation and analysis time. In addition, the 
method is suitable only for disulfide bonds containing only interchain disulfides.    
1.4.3.2 Intact (Non-reduced) Analysis 
An alternative approach to mapping disulfide bonds is by peptide mapping of non-
reduced protein digests (intact digests) without the need for reduced aliquots. The methods for 
disulfide bond assignment from non-reduced protein digests can be divided into three categories: 
methods involving post-column chemical or electrolytic reduction of the disulfide bonds, those 
involving gas-phase reduction of the disulfide bonds, and methods that do not involve cleavage 
of the disulfide bonds. In this section, we describe the methods that fall in the first two 
categories. For the last  category, the disulfide bonds are typically assigned by peptide mapping 
using CID data by calculating theoretical m/z’s (at different charge states) of the expected 
disulfide bonded peptides and searching the calculated m/z values in the MS data; the ions are 
assigned by identifying the characteristic fragment ions in the MS/MS spectra.
78,80
 Several 
automated tools have been developed to identify disulfide bonded peptides without cleaving the 
disulfide bond, and those are discussed in the automated tools section (Section 1.6).  
1.4.3.2.1 Post-Column Reduction Methods 
Several methods have been developed whereby non-reduced protein digests are separated 
by liquid chromatography followed by post-column partial reduction of disulfide bonded 
peptides prior to mass spectrometric characterization, typically with CID fragmentation. Post-
column reduction of disulfide bonds can be done chemically by introducing a reducing agent 
such as Tris (2-carboxyethyl) phosphine (TCEP), by in-source reduction during ionization, or 
23 
 
electrochemically via an increased potential on an electrochemical cell placed on the flow path 
from the column.  
Post-column chemical reduction of disulfide-bonded proteolytic digests typically 
involves separation of the non-reduced protein digests by reversed phase liquid chromatography, 
and the eluates from the column are mixed (via a mixing-tee) with an optimized amount of a 
reducing agent (e.g TCEP) to partially reduce the disulfide bonds, as demonstrated by Li et 
al.
97,98
 Since only partial disulfide bond reduction is done after LC separation, disulfide-linked 
peptides with intact disulfide bonds and their corresponding Cys-containing peptides that 
resulted from the disulfide bond reduction would have the same retention time and would both 
be detected in the same full scan mass spectrum.  To identify disulfide-bonded peptides, the 
extracted ion chromatograms of all Cys-containing peptides are compared, and the Cys-
containing peptides that have the same retention time are assigned as disulfide bonded.
97,98
 The 
assignments are confirmed by the presence of a disulfide-linked peptide at the same retention 
time with a molecular mass corresponding to the sum of the molecular masses of the two Cys-
containing peptides minus 2 Da.  Scrambled disulfide bonds are readily assigned in the same 
manner.
98
 Liu and coworkers
99
 used this approach to map the disulfide bonds of an IgG2 
antibody, but instead of using only LC-MS data, LC-MS/MS (CID) data were used for 
unambiguous characterization of the LC peaks of the disulfide bonded peptides and those of their 
corresponding Cys-containing peptides. 
Besides chemical reduction, in-source reduction during electrospray ionization can be 
used  for partial reduction of disulfide-linked peptides, as  shown by Cramer et al.
79
 Post-column 
in-source reduction, followed by HCD analysis of the partially reduced peptides, was used to 
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develop a method capable of assigning complex intra- and inter-chain disulfide bonds in 
proteins, including disulfide bonds involving closely-spaced Cys residues.
79
   
 Methods involving post-column electrochemical (EC) reduction of disulfide bonds prior 
to mass spectrometric analysis are also emerging approaches for disulfide bond characterization 
in proteins. Cramer et al 
100
 recently demonstrated that disulfide bond assignment in small 
proteins, such as human insulin, can be done by direct infusion of the intact protein into an 
electrochemical cell for partial reduction of DSBs of the intact proteins followed by tandem mass 
spectrometry (CID fragmentation) to confirm the sequence coverage of the protein. For larger 
proteins (e.g human serum albumin and ribonuclease B), proteolytic digestion and LC separation 
of the protein digests are necessary prior to post-column EC reduction of the disulfide-bonded 
peptides and MS/MS fragmentation (LC-EC-MS/MS), as recently demonstrated by Switzar et 
al.
101
 A rapid method employing on-column proteolytic digestion and electrochemical reduction 
was reported by Chen et al.
102,103
 In this approach, an online pepsin column is used for rapid 
digestion of intact proteins, and disulfide bonded peptides are partially or completely reduced 
using different electrochemical potentials, followed by desorption electrospray tandem mass 
spectrometry (DESI-MS/MS).
102
 This online digestion approach provides unprecedented 
digestion and reduction speeds (done in less than 10 mins) and very low potential for inducing 
disulfide artifacts due to less sample handling and pepsin digestion at low pH.   
In general, although the chemical and electrochemical post column partial reduction 
methods do save sample preparation time (compared to the case of reduced and non-reduced 
samples), optimizing the reduction conditions to get sufficient signals for both the reduced and 
non-reduced peptides is a major challenge.   
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1.4.3.2.2 Gas Phase Dissociation (Reduction) Methods 
Because ETD mainly cleaves disulfide bonds (gas phase reduction) leading to intense 
Cys-containing peptide product ions, several disulfide bond characterization methods have been 
developed that take advantage of the unique ETD fragmentation pattern to analyze non-reduced 
protein digests for disulfide bond mapping. Karger et al reported a method that combines 
alternating ETD/CID fragmentation (MS
2
) of the disulfide-bonded peptides and CID-MS
3
 





 This method is suitable to map disulfide-bonded peptides containing 
complex disulfide linkages, such as nested disulfides and cysteine knots,
71
 as well as peptides 
completely cyclized by a disulfide bond.
91
 However, due to the enormous data generated as a 
result of the additional CID
3
 step, the method may not be necessary for samples that do not 
contain complex disulfides. Recently, Massonnet and coworkers
93
 reported a similar technique 
for disulfide bond assignment of peptides containing two disulfide bonds. After opening of the 
disulfide bonds by ETD, the generated species are separated by ion mobility prior to 
characterization of the separated ions by CID fragmentation.
93
   
Clark et al reported a much simpler ETD-based method that is suitable for samples 
containing simple interchain disulfide-bonded peptides, including disulfides with multiple (three 
to four) disulfide bonded chains.
53
 The method does not require an MS
3
 step, and instead of 
searching the m/z’s of all expected (known) disulfides and possible scrambled disulfides, the 
extracted ion chromatograms (XIC’s) of all Cys-containing peptides are generated, and the ETD 
spectra of the peaks in the XICs are interrogated to determine the bonding partner(s) of the Cys-
containing peptides.
53,54
 Disulfide assignments are made when fragment ions of Cys-containing 
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peptides are identified in the same ETD spectrum, and the sum of their masses minus 2 Da (mass 
of 2H) match the mass of the expected disulfide. The c and z ions resulting from backbone 
cleavage of the bonded peptides can be used to further confirm the identities of the bonded 
chains.
54
 This XIC approach is suitable to map the disulfide bonds in proteins whose disulfide 
connectivity is unknown and also to quickly verify non-native or alternative disulfide bonds. In 
addition, the XICs of Cys-containing peptides can also provide information about any free Cys in 
the protein without the need for differential alkylation.
105,106
   
Similar to ETD fragmentation, ultraviolet photodissociation (UVPD) of simple interchain 
disulfide bonded peptides in the gas phase can be used to map disulfide bonds in proteins, as 
demonstrated by Agarwal et al.
90
 After separation of non-reduced protein digests using LC, 
irradiation of disulfide-linked peptides, including three chain disulfide-linked peptides, with laser 
pulses at 266 nm in an ion-trap mass analyzer led to selective cleavage of disulfide bonds, thus 
revealing the disulfide bonded peptides. However, backbone cleavage of the Cys-containing 
peptides is not typically observed using this approach.
90
 
1.5 Software for Automated Disulfide Bond Assignment   
Manual analysis of disulfide bonds in proteins is a challenging and time-consuming task 
that requires expertise in the field. As such, an increasing number of automated tools have been 
developed for rapid and high-throughput protein disulfide bond assignment using MS/MS data. 
Automated tools are ugently needed when large cohorts of samples need to be routinely 
analyzed, as is the case in biopharmaceutical industries. Most of the developed tools are based on 
the non-reduced analysis, although a few tools also have the option to map disulfide bonds by 
comparing data from reduced and non-reduced samples.  
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MassMatrix, developed about a decade ago, is one of the prominent tools for automated 
assignment of disulfide-linked peptides from non-reduced protein digests.
107
 Assignments are 
solely based on fragment ions from the backbone cleavage of the bonded peptides. This is a 
shortcoming of the tool, because only a limited number of ions are considered for disulfide bond 
assignment. Most importantly, fragment ions containing the disulfide bonds are not considered 





 can map disulfides from MS/MS data using several 
characteristic fragmentation peaks of disulfide bonded peptides, including b/y or c/z ions 
containing intact disulfide bonds. While DBond assigns dipeptides solely from CID data, and 
includes ions resulting from the occasional CID cleavage of C-S and S-S bonds (resulting in 
thioaldehydes, persulfides and dehydroalanin ions),
72,82
 the MS2DB+ software can assign 
disulfides from either CID or ETD data, and the fragment ions considered for CID data include 
ions resulting from the loss of water or ammonia from b/y ions. For both software products, the 
theoretical m/z’s of all possible disulfide-bonded peptides are searched from MS
1
 data, and their 
identified precursor ions are automatically assigned by comparing theoretical and experimental 
MS/MS spectra of the disulfide-bonded peptides. In addition, the tools score the assigned 
disulfide-bonded peptides based on the number of matched fragment ions and their intensities.  
A unique algorithm known as RADAR (Rapid Assignment of Disulfide Linkage via A1 ion 
Recognition) that assigns disulfide bonded peptides based on dimethyl labeling of the N-termini 
of the bonded chains was reported by Huang et al,
110
 and it has been applied for disulfide bond  
assignment in monoclonal antibodies.
111
 Dimethyl-labeled peptides produce intense a1 ion 
signals in CID spectra, which are used to screen for disulfide bonded peptides. Because these 
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species mostly contain two or more peptide chains, the CID spectra would have two or more a1 
ion peaks, and RADAR rapidly screens for disulfide-linked peptides by first searching for such 
spectra that contain multiple a1 ion peaks.
110
 Cys-containing peptides whose a1 ions are found in 
the same spectrum are considered to be disulfide bonded, and they are confirmed by matching 
the precursor ion mass to the molecular weight of the predicted disulfide-linked peptide, 
followed by assigning the fragment ions (b/y ions) resulting from fragmentation of the disulfide- 
bonded peptide chains.
111
 This approach is suitable for rapid identification of disulfides, 
including scrambled disulfides, because prior knowledge of the disulfide connectivity is not 
required. Intrachain disulfides on a single peptide can be assigned in a similar manner but instead 
of searching for multiple a1 ions in the CID spectra, a specific (target) a1 ion corresponding to 
the N-terminal of the peptide can be searched for. The software is effective for disulfide mapping 




Tools that assign disulfide bonds from HCD and EThcD data have also been developed 
within the last decade. A software tool known as pLink-SS was introduced in 2015 by Lu and 
coworkers for automated disulfide bond assignment in proteins using HCD data.
69
 The software 
was used to map simple and complex disulfides from a purified protein (IgG), a mixture of 10 
proteins containing 74 disulfide bonds, and at the proteome level (199 DSBs in 150 proteins 
from E. Coli) using HCD data.
69
 Another tool known as SlinkS assigns interchain and intrachain 
disulfide bonds by matching experimental MS/MS fragment ions from ETD and EThcD spectra 
to in silico fragments.
74
 For assignments from ETD data, the software searches for marker ions 
corresponding to the masses of the disulfide-linked peptides, as well as c/z ions with and without 
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disulfide bonds; while b/y ions are also included in the search when assigning disulfide bonds 
from EThcD data.  The assigned disulfide-linked peptides are scored, and FDRs are calculated 
based on user-defined cut-off values.  
Besides the aforementioned tools, several commercial software products are available for 
automated analysis of protein disulfide bonds connectivity using MS/MS data, particularly in 
protein pharmaceuticals. These include BioConfirm (Agilent Technologies), Byologic (Protein 
Metrics Inc), DisulfideDetect (Bruker), PepFinder, BioPharma Finder, and Pinpoint 
(ThermoFisher Scientific), BioPharmView (SCIEX), and BiopharmaLynx (Waters). While tools 
like DisulfideDetect require only non-reduced protein digest for disulfide analysis, PepFinder 
and BioPharma Finder can map disulfide-bonded peptides using either non-reduced protein 
digests or both reduced and non-reduced protein digests.  
Although the automated assignment of disulfide bonded peptides has facilitated disulfide 
analysis of proteins, there is still room for improvement in this field. Most of the tools developed 
so far can readily assign simple inter-chain disulfide-linked peptides but would not readily assign 
disulfide-bonded peptides containing complex intertwined disulfide linkages involving both 
interchain and intrachain disulfide bonds, nested disulfides, and dipeptides with more than one 
inter-chain disulfide bond (disulfide box). Although several approaches can be utilized to 
manually assign the disulfide bonds of these complex cases,
113
 software that can readily assign 
such disulfide-bonded peptides remain elusive.  
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1.6 Challenges and Summary 
1.6.1 Challenges in Disulfide Bond Analysis 
Despite the existence of high resolution mass spectrometers, automated tools, and several 
strategies to map disulfide bonds in proteins, there are still some challenges that can be 
encountered during disulfide bond assignments. When non-native disulfide bonds are identified 
after bottom-up disulfide analysis, it is difficult to tell if they are disulfide artifacts introduced 
during sample preparation or they are alternative disulfide bonds (disulfide variants) present in 
the sample. One way to verify if disulfide artifacts are introduced during sample preparation is to 
validate a particular method using a protein whose disulfide bond connectivity has been well 
characterized.
78
 In addition, top-down analysis of the intact protein requires less sample 
handling, and it would be an important first step in pinpointing the source of non-native disulfide 
bonds.
114
 Finally, when proteins have been identified to contain alternative disulfide bonds 
(disulfide-mediated isoforms), quantifying the amount of the protein that contains the native and 
alternative disulfide bonds remains a challenge because, many times, the disulfide-mediated 
isoforms would not be easily separated by standard separation techniques.  State-of-the-art 
separation methods are a possible route forward for solving this problem, though baseline 
separation of the isoforms remains a challenge.
115,116 
1.6.2 Summary of Disulfide Bond Analysis 
Disulfide bond mapping in proteins provides vital information regarding the disulfide 
bond connectivity pattern in the protein, and it is thus important to confirm the global disulfide 
bond structure of a particular protein and to verify whether or not any disulfide-mediated 
isoforms
5
  or variants
95
 are present. Several bottom-up mass spectrometry approaches, as 
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described herein, have been developed for this purpose. In silico digestion is an important first 
step for disulfide mapping to decide what enzyme (or combination of enzymes) to use for 
digestion in order to get simple disulfide bonded peptides that are easy to analyze, and to decide 
what fragmentation technique would be suitable for easy and rapid assignment of disulfide 
bonded spectra. The majority of disulfide mapping methods are based on CID and ETD 
fragmentation techniques, but with newer fragmentation techniques such as EThcD and HCD, 
new disulfide mapping methods involving these techniques will be developed in the future. From 
a data analysis point of view, software tools will need to be developed for automated 
characterization of disulfide-bonded peptides with complex disulfide bond connectivity.  Finally, 
quantitation of disulfide variants remains a challenge. 
1.7 Protein Glycosylation 
1.7.1 Overview of Protein Glycosylation 
Protein glycosylation, the covalent attachment of oligosaccharide chains to proteins, is a 
complex post-translational modification process that occurs in the endoplasmic reticulum (ER) 
and Golgi apparatus during protein synthesis in cells.
117
 This process of conjugating 
oligosaccharide chains (glycans) on proteins results in the formation of glycoproteins, and more 
than 50% of all proteins are glycosylated.
118









 glycosylation; with N- and O-
linked glycosylation being the most common types. N-linked glycosylation results from the 
attachment of N-glycans to a nitrogen atom on the side-chain of asparagine (N) amino acid 
residue while O-linked glycosylation results from the attachment of O-linked glycans to a 
hydroxyl group on the side chains of serine (S/Ser) or threonine (T/Thr) amino acid residues. 
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While the formation O-linked glycosylation only requires the presence of Ser and/or Thr amino 
acid residues, N-linked glycosylation requires the asparagine (N) residue to be within a 
consensus amino acid motif of N-X-S/T, where X could be any amino acid except proline.
117
 
However, not all asparagine residues in the glycosylation site motifs are glycosylated.   
Glycosylation plays critical structural and functional roles in glycoproteins, and it is also 
important during the development of glycoprotein-based biotherapeutics. Glycosylation can 
impact a protein’s folding, half-life, transportation, cellular interactions, as well as solubility.
124-
126
 In addition, changes in the glycosylation levels of endogenous proteins can provide 
information relating to disease progression.
127
 In recent years, several glycoproteins, especially 
monoclonal antibodies, have been used for the development of biotherapeutics to treat 
diseases.
128
 The glycosylation profiles of these drugs are important for cell line selection, 
optimization of cell culture process parameters during the recombinant synthesis of the proteins, 
ensuring batch-to-batch consistency during drug development, and for comparing biosimilars to 
innovator biologics.
129-132
 Glycosylation is also a major critical quality attribute of biologics that 
must be within a certain pre-determined range in order to ensure safety and efficacy of the drugs. 
Hence, identifying and characterizing the types of glycans attached to proteins is vital for 
effective development of efficacious and safe biotherapeutics and vaccines, for structural and 
functional studies of glycoproteins, as well as biomarker discovery for disease diagnosis.                
The attachment of glycans to proteins imparts tremendous complexity and diversity on 
the proteins due to the variety of N- and O-linked glycans that could be appended to the 
proteins.
133, 134
 Different types of glycans can occupy different glycosylation sites 
(macroheterogeneity) and/or the same glycosylation site (microheterogeneity). This macro and 
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micro glycosylation heterogeneity further increase the complexity of glycoproteins and presents 
an enormous challenge in protein glycosylation profiling.  Figure 4 shows some common N-
glycans that can be attached to proteins. Each of the glycans consists of a conserved core of two 
N-acetylglucosamine (GlcNAc) and three mannose (Man) residues. N-linked glycans fall into 
three main categories: high-mannose, hybrid, and complex glycans; and all three N-glycan types 
are formed from a precursor glycan (Glc3Man9GlcNAc2) via several enzymatic processes.
117
 






Figure 4. Examples of N-linked glycan structures. The monosaccharide residues include N-
acetylglucosamine (GlcNAc), glucose (Glc), mannose (Man), galactose (Gal), N-acetylneuramic acid 




1.7.2 Characterization of Protein Glycosylation 
Two main methods are commonly used for glycosylation profiling: Glycan analysis and 
glycopeptide analysis. Figure 5 illustrates the workflow for glycosylation analysis using these 
two approaches. Glycan characterization (Fingure 5A) requires the release of the glycans from 
the protein prior to analysis, typically by liquid chromatography and fluorescence and/or a mass 
spectrometric detection (LC-FLD or LC-MS/MS).
135-137
 N-glycans are usually released from 
glycoproteins using Peptide-N-Glycosidase F (PNGase F) enzyme. All glycans are naturally not 
fluorescent; hence, glycan analysis by LC-FLD requires derivatization of the released glycans 
with fluorescence tags (e.g 2-amino benzoic acid and RapiFluor) in order to enable fluorescence 
detection. The released and derivatized glycans are typically purified from the rest of the protein 
using solid phase extraction, and the purified glycans can be separated using hydrophilic 
interaction chromatography (HILIC).
135
 The glycan analysis approach provides information 
about the total glycan types present on a protein but glycosylation site-specific information is 




Figure 5. Representation of glycosylation analysis by released glycan approach (A) and glycopeptide 
approach (B). Red stars indicate derivatization of released glycans. The key of the glycan compositions 
(monosaccharide residues) is shown in Figure 4.  
 
Conversely, glycopeptide analysis (Figure 5B) provides site-specific glycosylation 
information, and it is the preferred method for glycosylation profiling of proteins containing 
more than one occupied glycosylation sites. The general approach for glycopeptide analysis 
involves enzymatic digestion of the glycoprotein (without glycan release) into peptides and 
glycopeptides, followed by electrospray ionization (ESI) or matrix assisted laser desorption 
ionization (MALDI) and mass spectrometry (MS) and/or tandem mass spectrometry (MS/MS) 
analyses.
133
 Typical enzymes used for glycoprotein digestion include trypsin and Lys-C. Liquid 
chromatographic separation of the peptides and glycopeptides by reverse phase columns (e.g C8 
36 
 
and C18 columns) prior to MS and MS/MS analysis is the most widely used method for 
glycopeptide profiling.  
In cases where the glycoprotein of interest is in a biological matrix that contains other 
proteins and glycoproteins, purification or enrichment of the glycoprotein is a vital step prior to 
glycan or glycopeptide characterization. A number of methods, including lectin affinity, gel 
electrophoresis, antibody binding, and solid phase extraction can be used for glycoprotein 
purification.
138-141
    
1.7.2.1 Glycosylation Analysis Using Mass Spectrometry 
Mass spectrometry is a powerful analytical method for glycosylation characterization. 
Glycans and glycopeptides can be analyzed using MALDI-MS, LC-ESI-MS and MS/MS, or LC-
FLD (for glycan analysis only).
142-144
 However, LC-ESI-MS/MS is the preferred characterization 
method, especially for glycopeptide assignments, as separation and fragmentation of glycans and 
glycopeptides provides unambiguous assignments. For LC-FLD characterization of fluorescent-
labeled glycans, mass spectrometry is typically used during method development to confirm the 
identities of the glycan peaks in the fluorescence profile (LC-FLD-MS).
135
  Hence, once the 
glycan peak identities in the fluorescence profile of a particular protein have been confidently 
assigned using mass spectrometry, subsequent routine glycan analysis of the protein can be done 
using only LC-FLD without mass spectrometric detection.
136
   
For glycopeptide analysis, high resolution MS and MS/MS data are typically used to 
determine the glycopeptide compositions, since MS data alone are not sufficient to assign 
isobaric glycopeptides. Glycopeptide analysis by tandem mass spectrometry can be done using a 
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variety of fragmentation techniques including electron transfer dissociation (ETD),
145, 146
 
collision induced dissociation (CID),
147





 and electron transfer higher energy collision induced 
dissociation (EThCD).
150
 A combination of more than one fragmentation technique provides 
thorough glycopeptide characterization.
148, 151
  Among these fragmentation techniques, ETD and 
CID are the most widely used dissociation methods.  
Glycopeptide analysis using both ETD and CID is highly desirable for unambiguous 
glycopeptide assignments because the two fragmentation techniques give complementary 
glycopeptide information. Figure 6 shows the characteristic dissociation behaviors of 
glycopeptides when subjected to ETD and CID conditions. Under ETD fragmentation 
conditions, the peptide components of glycopeptide compositions are cleaved while the glycan 
components remain intact (Figure 6A).
146
 Hence, ETD provides information about the peptide 
component of a glycopeptide composition without any information on the glycan component. On 
the contrary, glycosidic bonds are cleaved during CID fragmentation (Figure 6B) leading to 
dissociation of the glycans, and information about a glycopeptide’s glycan component can be 
obtained.
147
  In rare cases where unusually high CID energy is used, both the glycan and peptide 
components fragment, but the CID data are usually more complex and difficult to assign in such 
cases.
152, 153
 Generally, the cleavage of a glycopeptide’s glycosidic bonds during CID leads to 
loss of mono-, di-, tri-, and tetra- saccharide residues from the glycan component, giving rise to 
oxonium ions at m/z 366, 528, 690, and 657 (for glycopeptides containing sialic acids). In 
addition, CID spectra of glycopeptide compositions typically contain Y1 ions (peptide + GlcNAc 
ion)
154
 that can be used to determine the mass of the peptide portion of the glycopeptide. The 
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presence of the oxonium and Y1 ions in CID data indicates that the precursor ion is a 
glycopeptide. Nonetheless, the interpretation of glycopeptide data into meaningful glycosylation 
information is still very challenging.   
 
Figure 6. Representative spectra showing fragmentation of the same glycopeptide by ETD (A) and CID 
(B). During ETD fragmentation, the glycan component remains intact while the peptide component is 
cleaved, and during CID the glycan component is cleaved while the peptide component is typically not 
cleaved. Oxonium ion peaks at m/z 366 and 528 are observed in the CID spectrum (B). The blue squares, 
green circles, and red triangles denote N-acetylhexoseamine, hexose, and fucose monosaccharide 
residues, respectively. This figure is reproduced from Reference 145 with permission from the American 
Chemical Society.   
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1.7.3 Automated tools for Glycosylation Analysis 
Manual glycosylation characterization is a time-consuming and difficult task that requires 
expertise in the glycomics or glycopeptide analysis fields. Manual analysis becomes even more 
difficult when large cohorts of glycoproteins need to be routinely analyzed, as is the case in 
biopharmaceutical industries. Hence, numerous automated tools have been developed for rapid 
and high-throughput glycosylation analysis. Besides decreasing analysis time, automated tools 
are also advantageous because end-users of the tools don’t have to be experts in glycan or 
glycopeptide analysis in order to use them.  
A number of glycomics tools that utilize MS and MS/MS data for glycosylation profiling 
in proteins have been reported in the literature. Goldberg et al
155
 developed one of the early 
glycan annotation tools (Cartoonist) for automated assignment of released and permethylated N-
glycans using MALDI-MS data. The tool provides plausible glycan compositions from a 
database of structures that match the masses of peaks in the MALDI-MS spectra. 
Glycoworkbench functions in a similar manner, but instead of matching experimental peaks to 
glycan structures in a database, the peaks are matched to plausible glycan compositions provided 
by the user.
156
 Hu et al recently developed MultiGlycan-ESI,
157
 a tool that assigns permethylated 
glycans using LC-ESI-MS data.  Several automated glycomics algorithms for glycan assignment 




For automated glycopeptide analysis, GlycoMod
159
 and Glycopep DB
160
 are online tools 
that can be used to obtain potential glycopeptide compositions of a protein using MS data. 
However, these tools usually suggest a number of isobaric glycopeptide compositions for each 
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MS ion. Hence, further analysis using algorithms that can assign glycopeptides from MS/MS 
data is required for confident glycopeptide assignment. Recently, numerous tools have been 









are a fraction of software developed within the past three years (2015 to 2017) for glycopeptide 
analysis using MS/MS data. Generally, the tools assign glycopeptides to MS/MS data by 
comparing in silico spectra of the potential glycopeptide candidates to the experimental MS/MS 
spectra, and the potential glycopeptide candidate that best matches the experimental spectrum is 
assigned to the spectrum. A number of recent review articles that describe these tools and other 
automated glycopeptide software are available in the literature.
158, 165, 166
    
 The majority of the methods for glycopeptide analysis, including automated methods, are 
based on the well-established ETD and CID fragmentation techniques. Although these methods 
have significantly advanced the field of glycosylation characterization, development of high 
quality automated tools is still very challenging, and new approaches are needed to verify the 
accuracy of the automated tools in order to increase confidence in the results. Also, new 
automated methods are expected in the near future to accommodate fragmentation techniques 
like UVPD, HCD, and EThcD.  
1.8 Summary of Subsequent Chapters 
Chapter 2 describes a study to investigate the presence of disulfide bond-mediated 
structural isomers of endogenous IgG3 antibodies. A method combining ETD and CID data to 
map the disulfide bonds in proteins is used. Besides the classical IgG3 disulfide bonds, no 
alternative disulfide linkages were identified in the IgG3 molecules. This result indicates that 
unlike IgG2 and IgG4 that have isoforms resulting from alternative disulfide bond patterns, 
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native IgG3, like endogenous IgG1, does not have disulfide isoforms. In addition, the study 
demonstrates that when using ETD for disulfide bond analysis, an additional CID-MS
3
 step is 
not always necessary to confirm the amino acid sequences of disulfide-linked peptides, since 
product ions (c/z ions) from the disulfide-bonded peptides can be readily identified in the ETD 
spectra.  
Chapter 3 describes two new tools: Glycopeptide Decoy Generator and a large set of 
manually assigned glycopeptide CID data that ensure rapid assessment of existing scoring 
algorithms designed for glycopeptide identification from CID data. The tools also enable 
accurate development of CID glycopeptide software. Glycopeptide Decoy Generator generates 
abundant glycopeptide decoys de novo for any target glycopeptide composition. This work is 
important because developing high-quality scoring algorithms for the assignment of 
glycopeptides to MS/MS data is a challenging task and verifying the accuracy of the results from 
glycopeptide tools is vital in order to increase reliability on the tools. As a demonstration of the 
relevance of the new tools, they were used to assess the accuracy of GlycoPep Grader, an 
existing software that assigns glycopeptides to CID spectra. The results show that GlycoPep 
Grader has some limitations in scoring spectra from fucosylated glycopeptides, and these 
weaknesses were only identified when abundant decoys were generated by the decoy generator 
for each fucosylated target glycopeptide and scored against the CID spectra of the targets from 
the large dataset of glycopeptide spectra. These new tools are a useful contribution to the area of 
glycopeptide bioinformatics software development as they can advance the field by facilitating 
development of highly accurate scoring algorithms.  
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Chapter 4 describes a systematic study carried out to address GlycoPep Grader’s 
limitations in scoring fucosylated glycopeptides, and outlines proposals for improving the tool. 
The approach that was used to identify the root cause of GlycoPep Grader’s weaknesses can be 
applied to other glycopeptide scoring algorithm. After studying the CID fragmentation 
characteristics of fucosylated glycopeptides, product ions from an additional fragmentation 
pathway were identified and these ions were not incorporated into the original GlycoPep Grader 
scoring rules. Potential updates that take these new product ions into account are proposed.  
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Chapter 2: Disulfide Bond Characterization of Endogenous IgG3 Monoclonal 
Antibodies Using LC-MS: An Investigation of IgG3 Disulfide-mediated 
Isoforms 
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Abstract  
The use of monoclonal antibodies (mAbs) for the manufacture of innovator and 
biosimilar biotherapeutics has increased tremendously in recent years. From a structural 
perspective, mAbs have high disulfide bond content, and the correct disulfide connectivity is 
required for proper folding and to maintain their biological activity. Therefore, disulfide linkage 
mapping is an important component of mAb characterization for ensuring drug safety and 
efficacy. The native disulfide linkage patterns of all four subclasses of IgG antibodies have been 
well established since the late 1960s. Among these IgG subtypes, disulfide mediated isoforms 
have been identified for IgG2 and IgG4, and to a lesser extent in IgG1, which is the most studied 
IgG subclass. However, no studies have been carried out so far to investigate whether different 
IgG3 isoforms exist due to alternative disulfide connectivity. In an effort to investigate the 
presence of disulfide-mediated isoforms in IgG3, we employed a bottom-up mass spectrometry 
approach to accurately determine the disulfide bond linkages in endogenous human IgG3 
monoclonal antibody. Our results show that no such alternative disulfide bonds exist. While 
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many antibody-based drugs are developed around IgG1, IgG3 represents a new, and in some 
cases, more desirable drug candidate. Our data represent the first demonstration that alternative 
disulfide bond arrangements are not present in endogenous IgG3; and therefore, they should not 
be present in recombinant forms used as antibody-based therapeutics. 
2.1 Introduction 
Human IgG3 monoclonal antibody is the most efficient IgG subclass in mediating 
effector functions, followed by IgG1, IgG2, and IgG4, respectively.
1,2
 IgG3 displays the highest 
complement dependent cytotoxicity (CDC) and comparable antibody dependent cell-mediated 
cytotoxicity (ADCC) to IgG1, making it an ideal antibody drug candidate. Despite these ideal 
drug qualities and the rapidly growing use of monoclonal antibodies as biotherapeutics against 
various diseases, IgG3 is the only IgG subclass that has not yet been used for the production of 
antibody-based drugs. This is mainly due to its short half-life of seven days, compared to 21 days 
for the other IgG's.
3
 This short half-life of IgG3 is generally attributed to its long hinge region of 
62 amino acid residues, compared to 12 and 15 residues for the other IgG subclasses, making 
IgG3 more susceptible to proteolysis.
4
 However, a recent report by Stapleton et al. showed that 
the short half-life is primarily due to the presence of arginine at position 435 (R435) of the IgG3 
heavy chain, as opposed to histidine (H435) for the other IgG subclasses.
5
 Mutation of the IgG3 
heavy chain arginine 435 to histidine (H435–IgG3) extends the IgG3 half-life. This finding by 
Stapleton et al has energized interest in the production of IgG3-based biotherapeutics. 
Consequently, timely studies on the structure and properties of endogenous IgG3 are now 
an urgent priority. For example, Plomp et al recently identified three O-glycosylation sites (each 
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having about 10% site occupancy) in the hinge region of endogenous IgG3 samples from six 
donors.
6
 In a complementary line of work, we take on the challenge of investigating whether 
IgG3 is similar to the other IgG's in displaying endogenous isoforms resulting from alternative 
disulfide connectivity.  
Disulfide bonds are vital post-translational modifications in therapeutic proteins, as they 
play a key role in mediating protein folding, stability and biological function.
7–9 
The disulfide 
bond patterns of the four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) were established in the 
late 1960s and early 1970s by Milstein et al. using diagonal paper electrophoresis and Edman 
degradation.
10–14
 In addition to these classical IgG disulfide connections, alternative (non-
classical) disulfide bonds have been identified in the constant regions of some IgG subclasses, 
leading to their disulfide-mediated structural isoforms. For example, in addition to the classical 
IgG4 structure with interchain disulfide bonds in the hinge region, IgG4 also forms intra-chain 
disulfide bonds in the hinge region, thereby forming an isoform that consists of two half 
molecules.
15,16
 Additionally, both native and recombinant IgG2 antibodies have been shown to 
have two disulfide-mediated isoforms in addition to the classical IgG2 structure.
17–19
 
Furthermore, one report observed a trace amount of alternative intra-chain IgG1 disulfide bonds 
in the hinge region in addition to its conventional inter-chain disulfide bonds.
16 
However, there is 
currently no study determining whether IgG3 also contains disulfide-mediated isoforms. This 
lack of information is likely because IgG3 has been overlooked as a promising drug candidate, 
due to its short half-life, which is also reflected by the lack of IgG3-based drugs in the market. 
With the discovery of H435–IgG3, which has comparable half-life to IgG1, IgG2, and IgG4, it is 
important to confirm the classical IgG3 disulfide bond connectivity and to determine whether or 
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not disulfide-mediated isoforms exist in endogenous IgG3. Data from such a study would 
facilitate future drug development work based on the IgG3 scaffold, because it would provide a 
blueprint for the appropriate disulfide bonding profile for recombinant IgG3-based therapeutics.  
Herein, we use liquid chromatography coupled to tandem mass spectrometry (LC-
MS/MS) to experimentally characterize the disulfide bond connectivity of IgG3 for the first time. 
Two batches of native (endogenous) IgG3 were obtained from two different sources and 
extensive disulfide bond characterization was done by expanding upon our previously published 
extracted ion chromatogram/Electron Transfer Dissociation (XIC/ETD) approach for rapid 
disulfide bond analysis in proteins.
20
 With the combination of both the ETD-basedmethod and 
further analysis of collision induced dissociation (CID) data, all of the disulfide bonds in the 
constant region of the protein were accounted for. Using these techniques, we confirmed the 
classical disulfide bond pattern in the constant region of endogenous IgG3 antibodies and 
showed that unlike IgG2 and IgG4, which have well established conformational isoforms due to 
alternative disulfide bonds in their constant regions, endogenous IgG3 does not have any 
alternative disulfide bonds in its constant region and therefore does not have disulfide-mediated 
isoforms. 
2.2 Experimental  
2.2.1 Materials and Reagents 
Tris(hydroxylmethyl)aminomethane (Trizma) base, guanidine hydrochloride, sodium 
acetate anhydrous, acetonitrile, N-ethylmaleimide, and gamma-globulins from human serum 
were purchased from Sigma-Aldrich (St. Louis, MO). High capacity protein A resin, sodium 
phosphate, glycine hydrochloride, sodium chloride, calcium chloride dihydrate, and optima grade 
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formic acid were from Fisher Scientific (Pittsburgh, PA). Native human IgG3 was purchased 
from Fitzgerald (Acton, MA), mouse anti-human IgG3 antibody was purchased from Invitrogen 
(ThermoFisher Scientific, Grand Island, NY), sequencing grade trypsin was acquired from 
Promega (Madison, WI), and protein G resin was prepared in-house.  
2.2.2 Isolation of IgG3 from Human Gamma-globulins  
Gamma-globulins from human serum were used as a source of serum IgG. IgG3 was 
isolated by sequential affinity purification using protein A and protein G. Protein A binds to 
IgG1, IgG2 and IgG4, and protein G binds to all IgG subclasses. About 100 mg of gamma 
globulins was re-suspended in 20 mM sodium phosphate, 150 mM sodium chloride, pH 7.0 
(equilibration buffer) and passed over a protein A affinity column (5 mL bed volume of Pierce 
High-Capacity Protein A Ultralink resin) to capture all IgG subclasses except IgG3. The flow-
through from protein A column (containing IgG3) was collected and the IgGs retained in the 
column were eluted with 0.1 M glycine hydrochloride, pH 2.5 (elution buffer). The column was 
re-equilibrated with phosphate buffer and the flow-through was reloaded onto the column. The 
procedure was repeated to remove any residual IgG subclasses other than IgG3. To further purify 
the IgG3, the final flow-through from the protein A column was loaded onto protein G column (5 
mL bed volume of protein G resin), washed thoroughly with equilibration buffer (20x column 
volume), eluted with elution buffer, and immediately neutralized. IgG3 was dialyzed against the 
equilibration buffer, concentrated using Amicon ultra-centrifugal filters (30 kDa cutoff), and 
stored at -20 
◦
C. The isolated IgG3 was checked by SDS-PAGE and validated by Western blot 




To prevent disulfide bond shuffling, IgG3 samples were prepared under non-reducing 
conditions following a protocol modified from Reference 17. About 100 µg of IgG3 at a 
concentration of 1 µg/µL in 20 mM phosphate buffer (pH 7.0) was buffer exchanged using a 10 
kDa molecular weight cut-off filter (Millipore, Billerica, MA) into 100 mM acetate buffer (pH 
6.5) containing 7 M guanidine hydrochloride and 10 mM N-ethylmaleimide (NEM). The sample 
was incubated at 37 
◦
C for two hours to allow for denaturation and capping of any free cysteine 
residues. After denaturation and alkylation, excess NEM and guanidine hydrochloride were 
removed by subjecting the samples to centrifugal filtration using a 10 kDa molecular weight cut-
off filter, and the protein was reconstituted to a final concentration of 0.8 µg/µL in 100 mM Tris 
buffer (pH 7.0) containing 1 mM calcium chloride. Trypsin was added at an enzyme-to-protein 
ratio of 1:10 (w/w) and incubated for 15 hours at 37 
◦
C. Tryptic digestion was stopped by adding 
1 mL of formic acid for every 100 mL of solution. The digested IgG3 samples were diluted with 
water to a final concentration of 0.6 µg/µL and aliquots were stored at -20 
◦
C until analysis. For 
the purpose of reproducibility, samples from the same IgG3 source (Sigma-Aldrich or 
Fitzgerald) were digested on two different days and each digested sample was run at least two 
times on different days using the same experimental procedure as described in the LC-MS 
analysis section. 
2.2.4 LC-MS Analysis 
Digested IgG3 samples were analyzed using reversed phase HPLC (Waters Acquity, 
Milford, MA) coupled with a LTQ Orbitrap Velos Pro hybrid mass spectrometer equipped with 
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ETD (Thermo Scientific, San Jose, CA). A solution of 5 mL of the tryptic digest was injected 
onto a C18 Aquasil Gold column (100 x 1 mm i.d, 175 A
◦
, Thermo Scientific, San Jose, CA). 
The mobile phase A was 99.9% water with 0.1% formic acid; and mobile phase B was 99.9% 
acetonitrile with 0.1% formic acid. After sample injection, the tryptic peptides were eluted from 
the column at a flow rate of 50 µL/min using the following gradient: mobile phase B, initially 
held at 2% for 5 min, was increased to 35% in 55 min, and then ramped to 60% in 15 min, 
followed by a 10 minute isocratic elution at 95% B and re-equilibration.  
Data acquisition was done in the data-dependent scan mode. After a survey MS scan 
from m/z 400 to 2000 in the Orbitrap mass analyzer at a resolution of 30 000 at m/z 400, the top 5 
ions were sequentially selected for ETD (or CID, during CID experiments) in the linear ion trap. 
ETD and CID experiments were performed separately in different runs. For ETD experiments, 
charge state dependent ETD time and supplemental activation were enabled in order to enhance 
ETD efficiency. The ion–ion reaction time was maintained at 100 ms. For CID experiments, the 
activation time was set at 10 ms, and the normalization collision energy was 35%. The dynamic 
exclusion window and isolation width were set at 2 min and 2 Da, respectively, for both CID and 
ETD experiments. All data were collected in the positive ion mode with the ESI source spray 
voltage of 3.0 kV and capillary temperature of 250 
◦
C. The data were acquired and analyzed 
using Xcalibur 2.7 software (ThermoElectron Corp, San Jose, CA).  
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2.3 Results and Discussion  
2.3.1 Disulfide Analysis Approach 
Most disulfide assignments were done manually using an augmented version of a method 
reported elsewhere.
20
 A schematic representation of the disulfide mapping approach used to 
verify expected (classical) and alternative IgG3 disulfide bonds is shown in Figure 1A and B, 
respectively. To verify the classical disulfide linkage pattern, extracted ion chromatograms 
(XIC's) are constructed from ETD data based on the m/z values of two Cys-containing peptides 
that are expected to be linked through a disulfide bond (e.g. peptides P1 and P2, shown in Figure 
1A). The XIC's of the two peptides are then compared to quickly verify whether the expected 
disulfide bond is present. If peaks having the same retention time (RT) are identified (such as the 
highlighted peaks in the figure) the peptides are preliminarily assigned to be disulfide-bonded 
partners, and the corresponding ETD spectrum is inspected. ETD preferentially cleaves disulfide 
bonds and produces intense peaks for each bonded peptide,
20,21
 so the ETD spectrum is 
interrogated to determine whether intense marker ion peaks for peptides P1 and P2 are present, 
along with c and z fragment ions from each bonded chain and the intact disulfide-bonded 
peptide. If all these ions are present, the identity of the disulfide-linked peptides is assigned. 
Additionally, the assignment is quickly validated by matching the precursor ion mass to the 
theoretical mass of the dipeptide (the sum of the masses of the two Cys-containing peptides 
minus 2 Da).  
After confirming the presence of the classical disulfide-linked peptides, alternatively 
connected disulfide-linked peptides are also searched for in a similar manner (Figure 1B). For 
example, in addition to the correct disulfide bond between P1 and P2, if peptide P1 is also 
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alternatively linked to peptide P3, the XIC's of both peptides would have peaks where the P1–P3 
dipeptide (alternative disulfide bonded dipeptide) eluted. Therefore, by comparing the XIC's for 
peptides P1 and P3, and following the procedure described in the previous paragraph for 
identifying disulfide bonds between two peptides, the alternative disulfide bond between peptide 
P1 and peptide P3 could be identified, if it were present. Hence, to rapidly search for 
alternatively disulfide linked peptides, the XIC's of all Cys-containing peptides were compared, 
asking the question: are there any peaks that show up at the same retention time in at least two 
chromatograms, which could be aberrant disulfide linked peptides? When such peaks are 
identifiable, their ETD spectra are interrogated, as described above, to determine if the ion 







Figure 1. Schematic representation of the disulfide mapping approach for expected and alternative 
disulfides. (A) Assignment of an expected disulfide bond between Cys-containing peptides P1 and P2. 
Step 1: plot XIC's for each peptide. Step 2: identify peaks with the same retention time. Step 3: extract the 
corresponding ETD spectrum, which confirms the disulfide bond. Step 4: verify that marker ions of each 
chain (P1 & P2 peaks) and c and z ions from both chains are present in the ETD spectrum. (B) Alternative 
disulfide bonds are verified by the following: Step 1: plot and compare the XIC's of all Cys-containing 
peptides. Step 2: if peaks with the same RT are identified in the XIC's of peptides that are not expected to 
be disulfide bonded, steps 3 and 4 in (A) are used to verify whether the two peptides are bonded by an 
alternative disulfide bond. 
 
2.3.2 Assignment of Expected (classical) IgG3 Disulfide Bonds 
The classical disulfide bond structure of IgG3 is shown in Figure 2A. The comprehensive 
structure consists of 12 domains, two heavy chains and two light chains, with each chain having 
a variable and constant region. There are a total of 50 Cys residues that form 25 disulfide bonds: 
21 in the constant regions and four in the variable regions. Because the IgG3 samples used in this 
study were isolated from human serum, the amino acid sequences of the variable regions were 
unknown; therefore, only the disulfide bonds in the constant regions were mapped. Additionally, 
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disulfide bonds for both the lambda and kappa light chains were mapped. The expected tryptic 
disulfide bonded peptides from the constant region are shown in Figure 2B.  
 
 
Figure 2. (A) Structure of a typical human IgG3 antibody showing the disulfide bond pattern. There are a 
total of 50 Cys residues and 25 disulfide bonds (–S–S–). The red parts are the variable (V) regions and the 
black parts are the constant (C) regions. H and L indicate the heavy and light chains, respectively; VL and 
CL are domains of the light chain; VH, CH1, CH2, and CH3 are domains of the heavy chain. The hinge 
region has a 15-residue segment that is repeated three times. (B) Expected tryptic dipeptides from human 
IgG3 constant region. 
 
We verified the presence of these expected disulfide bonds prior to investigating disulfide 
bond variants. For example, Figure 3 shows XIC's and ETD data that support the assignment of 
the disulfide bonded peptide in the CH2 domain of the Fitzgerald IgG3 antibody. The XIC's of 
the CH2-1 (TPEVTCVVVDVSHEDPEVQFK) and CH2-2 (CK) Cys-containing peptides were 
plotted by searching ETD data in the m/z range of 1178–1181 (which encompasses the CH2-1 
theoretical m/z of 1179 in the plus two charge state) and 248–251 (which encompasses the CH2-
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2 theoretical m/z of 250 in the plus one charge state), respectively. This resulted in XIC's with 
intense peaks at the retention time of 37.5 min for both the CH2-1 peptide (Figure 3a) and the 
CH2-2 peptide (Figure 3b). The presence of peaks at the same retention time in both XIC's 
suggests that the two peptides are potential disulfide-bonded partners. To verify if they are 
connected, the ETD spectrum of the ion that eluted at 37.5 min was extracted (Figure 3c). The 
marker ion peaks for the CH2-1 and the CH2-2 peptides (at m/z 1179 and 250, respectively) were 
conspicuously present in the ETD spectrum, and c and z ions from the CH2-1 peptide, as well as 
c and z ions containing the intact disulfide bond (ions labeled in red) were identified, thereby 
confirming that the two peptides are indeed linked by a disulfide bond. Additionally, using high 
resolution data, the monoisotopic molecular mass of the precursor ion was determined to be 
within 3 ppm of the theoretical mass of the dipeptide. Hence the CH2 domain disulfide bond was 
assigned. The CH3, kappa and lambda constant light chain (CL), and the kappa and lambda 
heavy chain-light chain (HC-LC) domain disulfide bonds were assigned in a similar manner. 








Figure 3. XIC's and ETD spectrum showing assignment of the CH2 domain disulfide bond. (a) and (b) 
are XIC's of peptides TPEVTCVVVDVSHEDPEVQFK and CK, respectively; clearly showing the RT of 
the dipeptide (highlighted). The peptide sequence, theoretical m/z, and the m/z range that was used to plot 
the XIC's are shown in the inset. (c) ETD spectrum of the CH2 domain dipeptide. Marker ion peaks 
resulting from the cleavage of the disulfide bond are labeled in blue; product ions (c/z ions) not 
containing the disulfide bond are labeled in green; product ions containing the disulfide bond are labeled 





Figure 4. XIC's (a and b) and ETD spectrum (c) showing assignment of the classical disulfide bond in 
the constant region of IgG3 lambda light chain. See Figure 3 for color codes. 
 
 
2.3.3 Assignment of Disulfide Bonds between Identical Cys-containing Peptides 
Proteolytic digestion of IgG antibodies usually produces dipeptides with identical 
disulfide-bonded chains originating from the hinge regions of the antibodies. This happens 
because all IgG antibodies have inter-chain disulfide bonds in their hinge regions that link 
identical sequences of the heavy chains. For instance, IgG3 has four tryptic dipeptides (Hinge-1, 
Hinge-2, Hinge-3, and Hinge-4) that have identical disulfide bonded chains. Our previously 
published method for assigning disulfide bonds does not address this possibility; therefore, we 
have improved the method to account for these species. Because the disulfide bonded peptides 
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are identical, it may seem that the XIC data would not be useful for identifying them, since 
plotting the same XIC data twice results in two identical chromatograms. Nonetheless, we 
determined that the XIC's do, in fact, become useful if the charge states of the peptide marker 
ions are different for the two XIC's. For example, Figure 5 shows the assignment of the Hinge-1 
disulfide bond between two identical tryptic peptides (TPLGDTTHTCPR disulfide-linked to 
TPLGDTTHTCPR). Although the disulfide-bonded peptides are identical, by using charge states 
of 1 and 2 (corresponding to m/z 1298.6 and 649.8, respectively) distinct XIC's were obtained 
(Figure 5a and b), and the peaks in the two XIC's with the same retention time correspond to the 
disulfide-bonded dimers. The ETD spectrum of the XIC peak at RT 22.1 min (Figure 5c) shows 
the marker ion peaks at m/z 649 and 1298, along with c and z product ion peaks with and without 
the disulfide bond, labeled in red and green respectively. Additionally, the observed 
monoisotopic mass of the precursor ion was within 2 ppm of the theoretical mass of the expected 
Hinge-1 dipeptide, further confirming the assignment. The Hinge-4 disulfide-linked peptide, 
which also contains identical Cys-containing peptides linked by a disulfide bond, was assigned in 




Figure 5. Representative XIC’s (a and b) and ETD spectrum (c) that support the assignment of the 
Hinge-1 disulfide which has identical Cys-containing peptides. Since the peptides are identical, different 
charge states (+1 and +2) were used to plot their XIC’s so as to avoid plotting the same XIC twice. 
Details about the fragment ion colors are given in Figure 3. 
 
2.3.4 Disulfide Bonds Identified using CID Data 
Three expected disulfide-bonded peptides (in the Hinge-2, Hinge-3, and CH1 regions) 
were not readily assigned using the XIC/ETD method. The Hinge-2 dipeptide is small (CPEPK 
bonded to CPEPK), and the highest charge state identified for the dipeptide was two, which is 
not sufficient for efficient ETD fragmentation. Additionally, the presence of two proline residues 
prevented ETD cleavage before and after the proline residues, limiting the formation of c and z 
ions. The Hinge-3 dipeptide, which was also not rapidly detected using the XIC/ ETD method, 
contains two SCDTPPPCPR tryptic peptides connected by two disulfide bonds. In this case, 
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ETD data was acquired on the dipeptide, but the ETD spectrum showed only charged reduced 
species and no peptide marker ions. Therefore, the XIC's of the disulfide-bonded partners were 
not useful for assigning this dipeptide. The disulfide-bonded peptide in the CH1 domain also was 
not identified by the XIC/ ETD method because XIC's of these tryptic peptides did not show 
marker ions for the two peptide partners in the same ETD spectrum. The absence of these ions 
could be due to the large size of one of the tryptic peptides. The CH1-2 tryptic peptide is 63 
amino acids long (without any missed cleavage) and the Cys residue is 11 residues from the C-
terminus, leaving 52 amino acids after the disulfide bond. It is possible that because the portion 
of the peptide is very long, it could fold around the disulfide bond, thereby preventing efficient 
transfer of the ETD reagent ion to the disulfide bond and consequent cleavage of the bond by 
ETD. A shorter CH1 domain dipeptide may be obtainable using a different enzyme; in that case, 
the XIC/ETD method may be used to assign the disulfide bond.  
These three disulfide-linked peptides were assigned using a complementary strategy: 
searching for the in-tact disulfide-bonded peptides in the high resolution MS data first, followed 
by confirmation of the species using CID data, a procedure reported by Go et al.
22
 A prediction 
table containing the theoretical masses and m/z's of the dipeptides at different charge states was 
generated, and the XIC of each intact dipeptide was constructed from the total ion 
chromatogram. High resolution MS data and the corresponding CID spectra were used to assign 
the dipeptides. For instance, Figure 6 shows the assignment of the CH1 domain disulfide bond 
using this approach. The XIC of the ion at m/z 1130 was plotted (Figure 6A) and the 
corresponding high resolution mass spectrum at 53.3 min is shown in the insert. It contains five 
peaks at m/z 879, 989, 1130, 1319, and 1582, which correspond to the theoretical m/z's values of 
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the CH1 domain dipeptide at charge states of 9+, 8+, 7+, 6+, and 5+, respectively. Figure 6B 
shows the CID spectrum of the ion, m/z 1130, eluting at 53.3 min. Abundant b and y ions 
resulting from the fragmentation of both CH1 bonded peptides are present, and they are used to 
unequivocally confirm the CH1 disulfide-bonded peptide. This data analysis approach was also 
used for the assignment of the Hinge-2 and Hinge-3 disulfide-bonded peptides  
 
 
Figure 6. XIC and CID spectrum supporting the assignment of the CH1 domain disulfide bond.  (A) XIC 
of the CH1 domain tryptic dipeptide at m/z 1130 (7+). The insert shows the MS
1
 spectrum extracted from 
the XIC peak at 53.3 min. (B) CID spectrum of the 1130.86 ion (7+), supporting the assignment of the 
CH1 domain disulfide bond. Fragment ions (b/y) that contain the disulfide bond are labeled in red; 
fragment ions that do not contain the disulfide bond are labeled in green.  
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Overall, by combining two different MS-based approaches for assigning disulfide-linked 
peptides,
20,22
 we identified all the expected disulfide bonds in the constant region of endogenous 
IgG3 from two different sources. A summary of the disulfide bond assignments using the 
XIC/ETD method is shown in Table 1, and those identified using high resolution and CID data 
are shown in Table 2. 
 

















Unless otherwise stated, all ions are in the plus one charge state. 
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Table 2. Summary of Mass Assignments of Disulfide Bonds in Fitzgerald and Sigma IgG3 mAbs Using 




2.3.5 Assignment of Disulfide Bond Variants (Alternative Disulfide Bonds) 
After verification that all of the classical IgG3 disulfide bonds were present, we 
investigated the presence of alternative disulfide bonds. The same approaches used to identify 
the classical disulfide bonds were used to search for alternative disulfide bonds. For the 
dipeptides that were identified using the XIC/ ETD method, the XIC's of all the Cys-containing 
peptides were aligned and compared (Figure 7). In addition to the peaks that revealed the 
expected disulfide bonds (highlighted in blue), three sets of low abundant peaks in the XIC's of 
peptides that are not expected to be disulfide bonded were identified to have the same retention 
time (peaks at 19.2, 38.1 and 41.0 min), suggesting the possible presence of alternative disulfide 
bonds. To determine if the ions generating these peaks are aberrant disulfide-bonded peptides, 
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the corresponding ETD spectra were extracted and studied. None was found to correspond to 
disulfide-bonded peptides. For example, the XIC's of CPAPELLGGPSVFLFPPKPK (Hinge-4, 
P2, m/z 698.72 at charge state of three) and WQQGNIFSCSVMHEALHNR (CH3-1, m/z 
1129.02 at charge state of two), which are not expected to be disulfide bonded, both have peaks 
at 19.2 min, suggesting that they are potentially linked by an alternative disulfide bond. The MS 
data that generated the ETD spectrum of the ion that eluted at 19.2 min was interrogated. 
Immediately, this peak was confirmed not to be an aberrantly disulfide-bonded peptide because 
the precursor ion mass that generated this peak was from a 1267.6 Da ion, which does not match 
the theoretical mass of 4347.2 for disulfide-bonded CPAPELLGGPSVFLFPPKPK and 
WQQGNIFSCSVMHEALHNR. Hence, there was no alternative bond between these two 
peptides. After further interrogation, this particular peptide was assigned as the Hinge-2 
dipeptide with a non-specific N-ethylmaleimide alkylation (theoretical mass of 1267.6). The MS 
data for the peaks at 38.1 and 41.0 min were interrogated in a similar manner, and they were also 
found not be related to any alternatively linked peptides. Overall, no alternative disulfide bonded 
peptides were found between any Cys-containing peptides that are not expected to be disulfide- 
bonded.  
For the CH1, Hinge-2, and Hinge-3 domain disulfide bonds (see Figure 2B for the tryptic 
disulfide-bonded peptides), which were identified using high resolution (MS
1
) and CID data, a 
prediction table containing the masses and m/z values of plausible alternative disulfide bonds 
between these Cys-containing peptides and other Cys-containing peptides in close proximity was 
constructed, as described previously.
22
 This table includes six plausible four-peptide disulfide-
linked chains involving two SCDTPPPCPR peptides and three other Cys-containing peptides in 
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close proximity. The calculated m/z's were searched using high resolution MS and CID data, and 





Figure 7. XIC’s of Cys-containing peptides of the disulfides identified using the XIC/ETD method. 
Adjacent Cys-containing peptides of the same color (orange or black) are expected to be disulfide bonded 
and the peaks in their XIC’s that lead to the identification of the dipeptide are highlighted in blue. Peaks 
having the same retention time in XIC’s of peptides that are not expected to be disulfide bonded are 
indicated by asterisks of the same color. The peaks at 19.2 and 33.9 were interferences since they did not 
correspond to any dipeptide, while the peaks at 41.0 were the CH3 disulfide that showed up as 





In summary, no disulfide bond variants were detected, even though they were searched 
for using two different search strategies. It is theoretically possible that disulfide bond variants 
exist for IgG3 and remained undetected, but if that is the case, we expect these variants to be in 
very low abundance, perhaps less than 2% of the protein. This estimate is based on substantial 
prior work we have completed using these methods and mapping disulfide bond variants in HIV-
1 envelope proteins.
20,22–26
 In one case, the MS methods described here were able to detect an 




We carried out an extensive disulfide bond analysis of two endogenous human IgG3 
samples to experimentally verify the presence of the classical IgG3 disulfide bonds and to 
investigate the possibility of disulfide-mediated isoforms resulting from alternative disulfide 
bonds. All expected disulfide-bonded peptides in the constant regions of the IgG3 samples from 
two different sources were unambiguously assigned. Both the kappa and lambda forms were 
fully characterized in each protein. Although disulfide-mediated isoforms have been identified 
for IgG2 and IgG4 antibodies, and to a lesser extent in IgG1, the data presented herein show that 
there are no alternative disulfide bonded peptides within the constant region of native IgG3 
antibodies, indicating that endogenous IgG3 antibodies do not have disulfide-mediated isoforms. 
These data provide the first benchmark for a complete native IgG3 disulfide bonding profile, and 
the analytical approach described herein can be readily applied to recombinant IgG3 antibodies 
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Chapter 3: Two New Tools for Glycopeptide Analysis Researchers: a 
Glycopeptide Decoy Generator and a Large Dataset of Assigned CID Spectra 
of Glycopeptides 
The work described in this chapter encompasses an original publication in the Journal of 
Proteome Research: Jude C. Lakbub, Xiaomeng Su, Zhikai Zhu, Milani W. Patabandige, David 
Hua, Eden P. Go, Heather Desaire. J. Proteome Res., 2017, 16 (8), 3002-3008. It is reproduced 
here with permission from The American Chemical Society. 
 
Abstract 
The glycopeptide analysis field is tightly constrained by a lack of effective tools that 
translate mass spectrometry data into meaningful chemical information, and perhaps the most 
challenging aspect of building effective glycopeptide analysis software is designing an accurate 
scoring algorithm for MS/MS data.  Herein, we provide the glycoproteomics community with 
two tools to address this challenge. The first tool, a curated set of 100 expert-assigned CID 
spectra of glycopeptides, contains a diverse set of spectra from a variety of glycan types; the 
second tool, Glycopeptide Decoy Generator, is a new software application that generates 
glycopeptide decoys de novo.  We developed these tools so that emerging methods of assigning 
glycopeptides’ CID spectra could be rigorously tested. Software developers or those interested in 
developing skills in expert (manual) analysis can use these tools to facilitate their work.  We 
demonstrate the tools’ utility in assessing the quality of one particular glycopeptide software 
package, GlycoPep Grader, which assigns glycopeptides to CID spectra.  We first acquired the 
set of 100 expert assigned CID spectra; then we used the Decoy Generator (described herein) to 
generate 20 decoys per target glycopeptide. The assigned spectra and decoys were used to test 
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the accuracy of GlycoPep Grader’s scoring algorithm; new strengths and weaknesses were 
identified in the algorithm using this approach.  Both newly-developed tools are freely available 
to interested parties. The software can be downloaded at http://glycopro.chem.ku.edu/GPJ.jar. 
3.1 Introduction  
Glycosylation is a common but complex post-translational modification that occurs on 









 Changes in the 
glycosylation profiles of endogenous glycoproteins can serve as biomarkers for diseases 
diagnosis and progression.
6,7







 of glycoprotein-based drugs. Hence, extensive 
characterization of glycosylation on glycoproteins is vital in understanding important biological 
events and diseases, as well as the pharmacodynamics and pharmacokinetics of glycoprotein-
based drugs.   
 Mass spectrometry (MS) has become an invaluable analytical tool for glycosylation 
characterization due to its high sensitivity, high resolution, and complementary fragmentation 
techniques.
12
 Two main methods for mass spectrometric glycosylation analysis of glycoproteins 
are the glycan-based approach
13,14
 and the glycopeptide-based approach.
15,16
 While the former 
approach gives information about the total glycan pool on a glycoprotein, the latter approach 
provides glycosylation site-specific information. Because glycopeptide analysis is the method of 
choice for glycosylation profiling of proteins containing more than one glycosylation site, we 
focus on it herein.  Although advances in mass spectrometry instrumentation, sample 
preparation,
17,18
 and data acquisition methods
19,20
 have contributed to advances in glycopeptide 
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analyses, interpretation of the resulting mass spectrometry data from tandem MS experiments 
remains an additional ongoing field of development. 
An area of increasing interest in glycopeptide analysis is, therefore, the development of 
bioinformatics tools for rapid and automated assignment of glycopeptides to MS/MS data. 
Glycopeptides are typically analyzed by tandem mass spectrometry using fragmentation methods 
such as collision induced dissociation (CID), electron transfer dissociation (ETD), and higher 
energy collision dissociation (HCD). Manual analysis of glycopeptide data generated by these 
fragmentation methods provides the most confident glycopeptide assignments, but it is extremely 
time-consuming and requires extensive experience in data analysis. Hence, several 
bioinformatics tools have been developed for the interpretation of glycopeptide MS/MS data. 






 that assign 




 for assignment of glycopeptides to HCD 
spectra; and GlycoPep Detector
26
 and GlycoPep Evaluator
27
 for assignment of glycopeptides to 
ETD spectra. Other tools such as GlycoFragwork
28
 and GlycoMaster DB
29
 assign glycopeptide 
spectra based on a combination of two or more fragmentation techniques. A number of reviews 
that describe these tools, and others, in detail have been reported.
30-32
 In general, bioinformatics 
tools match glycopeptides to MS/MS data by scoring potential glycopeptide candidates against a 
particular MS/MS spectrum, and the candidate with the highest score is assigned to the 
spectrum.
21,26,27  
However, automated glycopeptide assignments can be problematic, as the best 
match for a spectrum can sometimes be an incorrect match. Therefore, it is vital for researchers 
to assess the accuracy of algorithms that assign glycopeptides to MS/MS data in order to ensure 
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confidence of the results; this rigorous testing also affords developers valuable information that 
can be used to improve the algorithms. 
Herein, we release two new bioinformatics tools to the community; they support 
glycopeptide analysis software developers and those assigning CID spectra of glycopeptides, 
either manually, or by an automated tool.  The first product, Glycopeptide Decoy Generator 
(GDG), rapidly generates abundant decoy glycopeptides de novo, and enables determination of 
the accuracy of tools that assign glycopeptides to CID data. Large numbers of decoys can be 
easily generated for glycopeptides using our tool. GDG generates abundant decoys for any target 
glycopeptide, and all the decoys have biologically relevant glycan components. The second 
product we provide herein is a dataset of 100 expert-assigned CID spectra of a diverse set of 
glycosylated peptides.  The dataset contains all major N-glycosylation types, including sialylated 
and fucosylated glycoforms.  We demonstrate the tools’ utility in assessing Glycopep Grader’s 
scoring algorithm; this tool assigns glycopeptides to CID spectra. Both newly-developed tools 
described herein are freely available to interested parties. 
3.2 Experimental  
3.2.1 Materials and Reagents 
Avidin, IgG1, bovine ribonuclease B (RNAse B), bovine fetuin, human apo-transferrin, 
Tris(hydroxylmethyl)aminomethane (Trizma) base, urea, dithiotreitol (DTT), iodoacetamide 
(IAM), and formic acid were purchased from Sigma-Aldrich (St. Louis, MO). IgG2 and IgG3 
were from Fitzgerald (Acton, MA), and sequencing grade trypsin was from Promega (Madison, 
WI). HIV-1 envelope glycoprotein samples, C.97ZA012 gp140 and A244-V1V2, were from the 
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Duke Human Vaccine Institute (Durham, NC). Ultrapure water was obtained via a Direct-Q 
water purification system (MilliporeSigma, Darmstadt, Germany).  
3.2.2 Sample Preparation 
For the HIV-1 Env proteins, the samples were prepared as reported in Reference 36. 
Briefly, about 100 µg of each of the proteins were dissolved in 100 mM Tris buffer (pH 8.0), and 
urea was added to a final concentration of 6 M to denature the proteins. Subsequently, DTT was 
added to reduce the disulfide bonds, and the reaction was allowed to proceed for 1 h at room 
temperature. After disulfide bond reduction, IAM was added to a final concentration of 10 mM 
and incubated for 1 h in the dark to cap free cysteine residues; followed by addition of excess 
DTT to react with excess IAM. The excess salt (urea and DTT) were either diluted to less than 
1M (for gp140) or removed by centrifugal filtration of the samples using 10 kDa molecular 
weight cut-off filters (for A244-V1V2), and the samples were reconstituted in Tris buffer (pH 
8.0) to a final concentration of 2 µg/µL. Finally, trypsin was added at an enzyme-to-protein ratio 
of 1:30 (w/w) and incubated for 18 h at 37 
◦
C, followed by a second trypsin addition at an 
enzyme-to-protein ratio of 1:30 (w/w) under the same conditions.  
For all other glycoproteins, the sample preparation was the same as described above, but 
with a slight modification during the digestion step. Trypsin digestion was done at 1:30 (w/w) 
enzyme-to-protein ratio for 18 h at 37 
◦
C, followed by a second trypsin addition at an enzyme-to-
protein ratio of 1:100 (w/w) for additional 3 h. After digestion, all samples were quenched by 
addition of 1 µL formic acid for every 100 µL of sample. The samples were analyzed 
immediately after digestion and/or aliquoted and stored at -20 C until analysis.  
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3.2.3 LC Separation and MS Data Acquisition 
LC-MS analysis was conducted on a Waters Acquity Ultra Performance Liquid 
Chromatography instrument (Waters Acquity, Milford, MA) coupled to either a LTQ Velos 
Linear Ion Trap or a LTQ Orbitrap Velos Pro hybrid Mass Spectrometer (Thermo Scientific, San 
Jose, CA). For avidin and the HIV-1 Env protein, C.97ZA012 gp140, data was acquired on the 
LTQ Velos Linear Ion Trap, and the column dimensions, gradient, and CID data acquisition 
settings are the same as those reported in Reference 27. For the remaining proteins, data was 
acquired on the LTQ Orbitrap Velos Pro. The Mobile Phase A was 99.9% LC/MS-grade water 
containing 0.1% formic acid and Mobile Phase B was 99.9% acetonitrile with 0.1% formic acid.  
A C18 Aquasil Gold column (100 x 1 mm i.d, 175 Å, Thermos Scientific, San Jose, CA) was 
used for reversed phase separation.  Sample solutions of 5 µL were injected onto the column and 
separated at a flow rate of 50 µL/min as follows: The mobile phase B was initially maintained at 
2% for 5 min followed by an increase to 35% in 60 min, and then ramped to 60% in 15 min.  
Mobile phase B was held at 95% for 10 min prior to re-equilibration of the column at 2% B for 
10 min.  
For both the LTQ Velos and the Orbitrap Velos Pro mass spectrometers, data-dependent 
acquisition was performed in the positive ion mode, and the acquisition parameters were 
optimized for each protein. The ESI source spray voltage was maintained at 3.0 kV and the 
capillary temperature was 200 
◦
C for HIV-1 C.97ZA012 gp140, 260 
◦
C for RNAse B, 275 
◦
C for 
IgG2, and 250 
◦
C for all other proteins.  In all experiments, a survey MS scan was obtained from 
m/z 400 or 500 to 2000 prior to CID fragmentation in the linear ion trap. For MS scans obtained 
in the Orbitrap mass analyzer, the resolution was set at 30,000 (at m/z 400).  CID spectra were 
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obtained by selecting the top 5 ions (top 8 for RNAse B) for CID fragmentation in the linear ion 
trap.  The CID normalization collision energy was 35% (30% for HIV-1 C.97ZA012 gp140) with 
an activation time of 10 ms and a 3 Da isolation window.  
3.2.4 Glycopeptide Spectral Library 
A library of glycopeptides’ CID spectra was generated using the following proteins: 
IgG1, IgG2, IgG3, bovine fetuin, RNAse B, avidin, transferrin, and two HIV-1 Env proteins 
(C.97ZA012 gp140 and A244-V1V2).  These glycoproteins, with the exception of A244-V1V2, 
have been well-characterized and reported in literature.
33-37
 For the glycopeptides that have been 
reported in literature, the dataset of manually characterized CID spectra was generated as 
follows: For each glycoprotein, a list of previously assigned glycopeptide compositions was 
compiled, and the theoretical monoisotopic m/z values at different charge states were computed 
and searched for in the MS data file of the glycopeptide digest of the protein. When a match was 
found, we determined if the peak was selected for CID fragmentation.  If a corresponding CID 
spectrum was found within 1 minute of the retention time of the peak in the full-MS scan, and if 
characteristic glycan oxonium ions (e.g ions at m/z 366, 528, and 690) were identified, the 
spectrum was manually assigned based on knowledge of glycopeptide fragmentation under CID 
conditions.  For A244-V1V2, which has not been reported in the literature, the glycopeptides 
were assigned using a previously described workflow for characterizing glycosylation on 
complex glycoproteins.
36,38
 Briefly, compositional analysis of glycopeptides was carried out by 
first doing an in silico digestion of the protein to find peptides with the N-X-S/T glycosylation 
site motif; then CID spectra were identified that contained an abundant ion consistent with the Y1 
ions
39,40
  (ions which are typically used to identify the peptide portions of glycopeptide 
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compositions) that would be generated from these glycopeptides.   Once candidate CID spectra 
were identified in this way, plausible glycopeptide compositions were obtained using high-
resolution MS data and GlycoPep DB.
41
 Potential glycopeptide candidates with experimental 
monoisotopic m/z values within 10 ppm from the theoretical m/z of the glycopeptide reported by 
GlycoPep DB were confirmed manually by annotating the glycosidic cleavages observed in the 
CID data. Overall, for all the proteins, each confirmed glycopeptide assignment in the dataset 
met the following criteria:  (1) the experimental monoisotopic mass of the precursor ion closely 
matched the theoretical monoisotopic mass of the assigned glycopeptide (within 10 ppm for 
Orbitrap data and 30 ppm for LTQ Velos data); (2) the CID spectrum contained an intense Y1 
ion of the glycopeptide; (3) the CID spectrum contained all or some of the following 
characteristic oxonium ion peaks: m/z 366, 528, 690, and 657 (for sialylated glycopeptides); and 
(4) glycosidic cleavages consistent with neutral losses of the monosaccharides present in the 
glycopeptide were observed. The Supplemental Data includes 13 example annotated spectra.  
Furthermore, the peaklists for all one hundred CID spectra are supplied in the Supplemental 
Data, along with their assigned glycopeptide compositions.  These spectral data can be used by 
other software developers who wish to test CID algorithms against expert-verified, pre-assigned 
data. 
3.3 Results and Discussion  
3.3.1 Tool 1: The Glycopeptide Decoy Generator  
Glycopeptide Decoy Generator (GDG) is a free tool designed to generate abundant 
glycopeptide decoys for accurate assessment of glycopeptide scoring algorithms that match CID 
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spectra to glycopeptide compositions. Figure 1A shows the graphical user interface of the decoy 





Figure 1. Graphical user interface of Glycopeptide Decoy Generator showing (A) the “Input Data” menu 
and parameters to generate 20 decoys for a target glycopeptide; and (B) the “Result” menu showing 20 





To generate decoys, the user enters the monoisotopic m/z value and charge state of the 
target glycopeptide composition (target), the number of decoys to generate, as well as the desired 
mass tolerance (in ppm) of the decoys from the target.  In addition, the peptide and glycan 
portions of the target glycopeptide are entered in two adjacent windows with each peptide 
portion aligned with its glycan portion. The decoys generated by GDG can be divided into three 
categories based on their glycan compositions, and the user may enter the number of decoys 
required for each category (“Num from Each Category”). The three decoy categories are: (I) 
decoys containing [HexNAc]2[Hex]1-n[Fuc]0-2, where n is any integer greater than 1; (II) 
decoys containing [NeuNAc], and (III) decoy glycopeptides not belonging to categories (I) or 
(II). If the sum of the numbers entered for each decoy category is lower than the total number of 
decoys entered by the user, the software randomly adds decoys from all three categories to make 
up the total number of decoys required.  Finally, if the peptide portion contains a cysteine (Cys) 
residue, the user must specify whether or not the cysteine residue is modified.  The current 
version of GDG has options for cysteine modification using iodoacetamide, iodoacetic acid, and 
vinyl pyridine, which are the commonly used Cys alkylating agents. For any other modification, 
including cysteine modification with other alkylating agents like N-ethylmaleimide, the mass of 
the modification can be entered in brackets after the amino acid residue that is modified. For 
example, if the peptide DETMFNASQR has Met oxidation, it would be entered as 
DETM(+15.99)FNASQR. The “Input tips” field at the bottom of the software provides guides 
with regards to the aforementioned parameters that have to be entered in the “input data” menu. 
In this study, decoys were generated at a target-to-decoy ratio of 1:20, the “mass/charge 
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tolerance" was set at 20 ppm, the number of decoys from each category was 3, and 
iodoacetamide was selected for Cys modification of all Cys-containing target glycopeptides. 
Once all the “Input Data” parameters have been entered, and the user clicks the 
“Generate Decoy Glycopeptides” button, the software generates the decoys.  The decoy list is 
displayed in the “Result” page of the software, and an example output file is shown in Figure 1B. 
The figure shows 20 glycopeptide decoys generated for the target glycopeptide and input 
parameters displayed in Figure 1A. The decoys have varying glycan compositions, and their 
monoisotopic m/z’s are close (within 20 ppm) to that of the target glycopeptide.   
3.3.2 How GDG Generates Glycopeptide Decoys 
Figure 2 shows a schematic representation of the approach used by GDG to generate 
decoys. To create a decoy for any target glycopeptide, GDG uses two main steps. First, a glycan 
is randomly selected from a library of over 300 biologically relevant N-linked glycans, and 
secondly, a peptide mass is generated.  To choose a glycan for the decoy, the software queries a 
library of glycans that has been parsed into three categories (described in the preceding section), 
so that decoys of diverse glycan compositions could be easily generated. After a random glycan 
is selected, the algorithm determines if the selected glycan had been previously picked to 
generate a decoy for the same target.  If so, the software discards the glycan and selects a new 
glycan.  After selecting a non-redundant glycan from the library, the second step of decoy 
generation is to identify an appropriate peptide mass.  The mass that represents the peptide 
portion of the decoy is computed such that the m/z of the entire decoy (peptide + glycan portions) 
is within the user-specified mass tolerance from the m/z of the precursor ion.  The randomly 
selected glycan plus its arbitrary “peptide” mass represents the decoy. One final restriction is 
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placed on the decoy:  The mass appended to the glycan must not be smaller than the sum of the 
monoisotopic masses of asparagine and lysine amino acid residues. Once a decoy is generated, it 
is added to a restriction list to avoid duplication, and more decoys are subsequently generated 
until the user-specified number of decoys has been created. GDG can generate up to 45 decoys 
per target. The decoys are generated irrespective of the glycan type on the target or the enzyme 
used for digestion of the glycoprotein. 
 
 
Figure 2. Schematic representation of the decoy generation approach used by GDG. Decoys are 
generated via two main steps: First, a glycan is randomly selected from a pool of about 300 biologically 
relevant N-linked glycans separated in three categories (see text); and second, an arbitrary mass, 
representing the decoy’s peptide portion, is added to the glycan so that the total mass of the decoy is 
within a user-specified mass tolerance from the target glycopeptide mass. 
94 
 
3.3.3 Tool 2:  The Glycopeptide Spectral Library   
We collected a significant dataset of 100 CID spectra of known glycopeptide compositions; these 
spectra can be used for testing any glycopeptide scoring algorithm that accepts CID spectra.  
Figure 3 shows one example CID spectrum in the dataset.  This CID spectrum is from IgG1 
monoclonal antibody, and the data was assigned to the glycopeptide composition 
EEQYNSTYR+[Hex]3[HexNAc]5[Fuc]1. This glycopeptide had been previously assigned as 
being present in this particular protein.
33
 Along with all spectra in the dataset, the monoisotopic 
m/z of this glycopeptide matches the theoretical mass quite closely.  The doubly charged 
precursor ion, m/z 1419.0697, is within 2 ppm from the theoretical value, m/z 1419.0663.  In 
addition to matching the high-resolution mass, inspection of the CID data indicates that oxonium 
ions at m/z 528.2 and 690.1 are present, further confirming that the precursor ion is indeed a 
glycopeptide. By also identifying the Y1 ion, and confirming neutral loses of monosaccharide 
residues from the potential glycopeptide, the spectrum was assigned as 
EEQYNSTYR+[Hex]3[HexNAc]5[Fuc]1. In a similar manner, the 100 CID spectra in the 
MS/MS dataset were unambiguously assigned to their known glycopeptide compositions. The 
dataset consists of spectra from 33 high-mannose glycopeptides, 34 fucosylated glycopeptides 
and 33 non-fucosylated complex/hybrid glycopeptides. The glycopeptide compositions assigned 
to these spectra are henceforth referred to as target glycopeptides (or targets).  The peaklists for 
all CID spectra, and their assigned glycopeptide compositions, are available at 
http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.7b00289 (the Supporting Information of the 
original publication included in this chapter). In addition, 13 of the spectra are annotated.  See 




Figure 3. Representative CID spectrum showing the assignment of an IgG1glycopeptide (shown in 
figure). Glycosidic cleavages of the glycan portion and glycan oxonium ions are observed. The Y1 
product ion and neutral monosaccharide losses from the potential glycopeptide candidate (at m/z 1419.1) 
were used to confirm the assignment. The 100 spectra in the “Glycopeptide Spectral Library” were 
assigned to their correct glycopeptide compositions in the same way.  The blue squares, green circles and 
red triangles denote N-acetylhexoseamine, hexose, and fucose monosaccharide residues, respectively.  
 
 
3.3.4 Application of Tools 1 and 2 for Evaluating the Accuracy of CID Scoring Algorithms for 
Glycopeptides 
Figure 4 shows how the two new tools described above (Glycopep Decoy Generator and 
the large dataset of CID spectra) can be used to assess the accuracy of software that assign 
glycopeptides to CID data.  
The dataset of 100 CID spectra described in Section 3.3.3 of this dissertation and known 
targets for each spectrum was used in conjunction with the Decoy Generator to demonstrate how 
these tools are helpful in testing and refining glycopeptide analysis software.  Specifically, the 
scoring algorithm of GlycoPep Grader
21
 was evaluated herein. GlycoPep Grader uses 
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monosaccharide neutral loses from glycopeptide compositions to score target and decoy 
glycopeptides against a CID spectrum, and the candidate with the highest score is assigned to the 
spectrum in question.
21
 For each of the 100 target glycopeptide compositions, and the 100 
assigned spectra, 20 decoys were generated using the Decoy Generator, and GlycoPep Grader 
was used to score each target and its 20 decoys against the known CID spectrum of the target. 
The scores were interrogated to determine whether GlycoPep Grader consistently matched the 
CID spectra to their correct glycopeptide compositions or to decoy glycopeptides. 
 
 
Figure 4. Schematic representation of a simple approach to assess the accuracy of CID scoring 
algorithms. A tool is tested by using a large dataset of CID spectra (1), abundant decoys for each target 
glycopeptide in the dataset generated using the Decoy Generator (2). The spectra in the library scored 
against their known targets along with the abundant decoys generated by GDG.  Algorithms that have 
some weaknesses will match more spectra to decoys.     
 
A summary of the results is shown in Figure 5A. As shown, all the 33 spectra originating from 
high-mannose glycopeptides were matched to their correct targets; one out of the 33 spectra (3%) 
from non-fucosylated glycopeptides was matched to a decoy glycopeptide (32 spectra matched 
97 
 
the correct targets), while 12 out of the 34 spectra (35%) from fucosylated glycopeptides were 
matched to decoys (22 spectra matched to the correct targets). The results clearly indicate that 
GlycoPep Grader accurately scores spectra of high-mannose and non-fucosylated 
complex/hybrid glycopeptide compositions, but it has some weaknesses in scoring spectra of 
fucosylated glycopeptides. Hence, GlycoPep Grader’s scoring algorithm can be modified to 
improve its accuracy in scoring spectra of fucosylated glycopeptide compositions.  The 
annotated CID spectra of the 13 glycopeptides that were incorrectly assigned to decoys are 
available at http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.7b00289 (the Supporting 







Figure 5. Bar graphs showing results of scoring 33 high mannose, 33 non-fucosylated hybrid/complex 
(H/C), and 34 fucosylated hybrid/complex glycopeptide spectra scored against the known target 
glycopeptide compositions along with (A.) abundant decoys (20 decoys) per target glycopeptide and (B.) 
few decoys (three to five) decoys per target glycopeptide. More spectra of fucosylated glycopeptides were 
matched to decoys when abundant decoys were used (box).   
 
3.3.5 Are Abundant Decoys Needed for Accurate Evaluation of Glycopeptide Scoring 
Algorithms? 
After using abundant decoys, generated by the Decoy Generator, to identify the weakness 
in GlycoPep Grader’s scoring algorithm, we wanted to determine why the limitation was not 
identified during the development of the software.  In the original publication describing 
GlycoPep Grader,
21
 a total of 79 glycopeptides were scored using the software, and all 79 
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glycopeptides, including 17 fucosylated glycopeptides, were correctly assigned to the known 
glycopeptide spectra, even when scoring each spectrum against decoys.  In that work, typically 
3-5 decoys were used.  Hence, for this case study, we replicated the procedure used to generate 
decoys during the initial development of GlycoPep Grader, and we scored those decoys and 
targets against our new dataset of 100 CID spectra.  We used the same number of decoys per 
target glycopeptide (three to five decoys), and we generated the decoys in the same manner as 
described previously:  For each of the 100 target glycopeptide compositions, either three, four, or 
five decoys were generated from Titin, a glycoprotein containing about 50,000 amino acid 
residues, and a database of about 200 glycans that were multiplexed to the protein in silico, as 
described by Woodin et al.
21
 Each target and its decoys were scored against the known CID 
spectrum of the target using GlycoPep Grader. The results are shown in Figure 5B. The 33 
spectra of high-mannose glycopeptides and the 33 spectra of non-fucosylated glycopeptides were 
all matched to their correct glycopeptide compositions, and only one out of the 34 spectra of 
fucosylated glycopeptides was matched to a decoy. Hence, of the 100 target glycopeptides 
scored with limited numbers of decoys, 99 were matched to the correct target glycopeptides and 
only one spectrum was matched to a decoy. This result is contrary to the aforementioned case 
when the target-to-decoy ratio was 1:20, and up to 13 spectra (12 of which were of fucosylated 
glycopeptides) were assigned to decoys. A comparison of the scores of the 12 spectra from 
fucosylated glycopeptides that were assigned to decoys when scored at a target-to-decoy ratio of 
1:20 and the scores of the same spectra when scored against fewer decoys is provided in 
Supplemental Tables 1-12 of the original publication that is included in this chapter (available at 
http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.7b00289).  Table 1 shows an example of the 
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scores of one of the 12 spectra that was assigned to the target glycopeptide when scored against a 
few decoys (Table 1A) but it was wrongly assigned to a decoy when scored at a target-to-decoy 
ratio of 1:20 (Table 1B).   
Overall, the results indicate that GlycoPep Grader’s limitation in scoring spectra from 
fucosylated glycopeptides could not be determined by scoring target glycopeptide spectra against 
a limited number of decoys, which explains why GlycoPep Grader’s weakness was not identified 
during the development of the tool, when between three to five decoys per target were used. 
Hence, abundant decoys are indeed needed for accurate assessment of tools that assign 
glycopeptides to MS/MS spectra.  
Given the above results, it is imperative for software developers to use large numbers of 
decoys to test their scoring algorithms during the development of software designed to match 
glycopeptides to MS/MS data. By so doing, the probability of decoy matches increases, and 
when decoys outscore glycopeptide candidates that are known to be correct, software developers 
can easily make changes to improve the scoring algorithm. Similarly, end-users of glycopeptide 
software can assess the quality of the output from various tools by testing them against large 
spectral libraries of known glycopeptide compositions and large numbers of decoys per target 
glycopeptide. However, generating a large spectral library is time consuming. Hence, the peak 







Table 1: Results of scoring a fucosylated target glycopeptide against its known spectrum (shown 
in Figure 3) together with (A.) 5 decoys and (B.) 20 decoys 
 
 
A. Target-to-decoy ratio of 1:5 
  
Name Composition Mono m/z Score 
Target EEQYNSTYR+[Hex]3[HexNAc]5[Fuc]1 1419.0663 83.08 
Decoy1 AYANVSSKCSK +[Hex]5[HexNAc]4 1419.0862 20.22 
Decoy2 VNVSSSK+[Hex]5[HexNAc]5[NeuNAc]1 1419.0762 16.50 
Decoy3 YQSNATLVCK+[Hex]5[HexNAc]3[NeuNAc]1 1419.0805 16.50 
Decoy4 NTSDVMYKK+[Hex]4[HexNAc]4[NeuNAc]1 1419.0805 16.50 
Decoy5 QNQTLYSQK+[Hex]6[HexNAc]3[Fuc]1 1419.0894 0.00 
    
 
B. Target-to-decoy ratio of 1:20 
  
Name Composition Mono m/z Score 
Target EEQYNSTYR+[Hex]3[HexNAc]5[Fuc]1 1419.0663 83.08 
Decoy1 Peptide (1334.5734)+[Hex]3[HexNAc]5 1419.0717 83.25 
Decoy2 Peptide (1131.4316)+[Hex]3[HexNAc]6 1419.0405 40.44 
Decoy3 Peptide (485.2852)+[Hex]5[HexNAc]4[NeuNAc]2[Fuc]1 1419.065 33.50 
Decoy4 Peptide (661.2745)+[Hex]5[HexNAc]6[Fuc]1 1419.0437 29.37 
Decoy5 Peptide (834.3829)+[Hex]5[HexNAc]3[NeuNAc]2 1419.0453 28.68 
Decoy6 Peptide (938.4758)+[Hex]4[HexNAc]4[NeuNAc]1[Fuc]1 1419.0862 26.80 
Decoy7 Peptide (1594.6456)+[Hex]3[HexNAc]3[Fuc]1 1419.0573 23.93 
Decoy8 Peptide (1959.7656)+[Hex]2[HexNAc]2[Fuc]1 1419.0513 22.33 
Decoy9 Peptide (1133.5523)+[Hex]8[HexNAc]2 1419.0741 18.21 
Decoy10 Peptide (280.2338)+[Hex]7[HexNAc]7 1419.0869 16.50 
Decoy11 Peptide (1416.5875)+[Hex]5[HexNAc]3 1419.0521 16.50 
Decoy12 Peptide (340.2967)+[Hex]5[HexNAc]4[NeuNAc]3 1419.0895 16.50 
Decoy13 Peptide (266.1611)+[Hex]6[HexNAc]5[NeuNAc]2 1419.0402 16.50 
Decoy14 Peptide (395.29485)+[Hex]7[HexNAc]5[NeuNAc]1 1419.0857 16.50 
Decoy15 Peptide (1943.842)+[Hex]3[HexNAc]2 1419.0869 11.17 
Decoy16 Peptide (499.2631)+[Hex]6[HexNAc]6[Fuc]1 1419.0644 10.05 
Decoy17 Peptide (1781.7508)+[Hex]4[HexNAc]2 1419.0677 8.38 
Decoy18 Peptide (1797.7531)+[Hex]3[HexNAc]2[Fuc]1 1419.0714 8.38 
Decoy19 Peptide (1619.6457)+[Hex]5[HexNAc]2 1419.0415 0.00 
Decoy20 Peptide (1457.6558)+ [Hex]6[HexNAc]2 1419.073 0.00 
    
Note: The annotated CID spectrum of the target glycopeptide is shown in Figure 3. The decoy that 





3.4 Conclusion  
To simplify the task of building effective glycopeptide software, we developed two new 
tools, Glycopeptide Decoy Generator (GDG) and an expert-assigned dataset of 100 CID spectra.  
GDG rapidly generates glycopeptide decoys de novo, and these decoys can be used to assess the 
quality of tools that assign glycopeptides to CID data. As a secondary contribution, we provide 
herein peak lists for 100 validated CID spectra that can be used to test any existing software tool 
or any new tool under development.  Using large numbers of decoys generated by our newly 
developed tool, and our set of 100 validated CID spectra, we evaluated the accuracy of existing 
software that assigns glycopeptides to CID data.  We demonstrate that limitations in the scoring 
algorithm of the software can be identified when testing it against large sets of decoys, and these 
limitations could not be identified when only a few decoys were scored.  
Our tool is the first software that automatically generates abundant decoys on demand for 
the assessment of algorithms that assign glycopeptides to CID spectra. The approach for decoy 
generation is simple; it can be used as-is, or the software can be easily incorporated into other 
bioinformatics tools designed to match glycopeptides to CID data. The software can be 
downloaded at http://glycopro.chem.ku.edu/GPJ.jar. 
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Chapter 4: CID Fragmentation Patterns of Fucosylated Glycopeptides: 
Toward an Improved GlycoPep Grader Software 
 
Abstract 
GlycoPep Grader is one of many bioinformatics tools developed in recent years to 
facilitate the tedious task of assigning glycopeptides to MS/MS spectra. GlycoPep Grader 
assigns glycopeptides to CID data by searching for two types of product ions: (1) [peptide + core 
component] product ions, which are used to score ions that contain the peptide plus components 
of the pentasaccharide core, and (2) [precursor – monosaccharide] ions, which are used to score 
ions resulting from neutral loss of monosaccharide residues from the candidate precursor ion.  In 
Chapter 3, we assessed the accuracy of GlycoPep Grader’s scoring algorithm and found that 
while the tool accurately scores CID spectra from high mannose and non-fucosylated 
glycopeptides, it had some limitations in scoring spectra from fucosylated glycopeptides. Herein, 
we study the CID fragmentation characteristics of fucosylated glycopeptides and GlycoPep 
Grader’s scoring rules in an effort to solve the problem of wrongly assigned data from 
fucosylated glycopeptides. We identified some prominent product ions from a fragmentation 
pathway that was not considered when writing GlycoPep Grader’s rules for scoring fucosylated 
glycopeptides. Based on this finding, we propose new scoring rules for fucosylated glycopeptide 
compositions that can be incorporated into GlycoPep Grader to increase the scores of fucosylated 
glycopeptides.  The approach used here to improve the scoring algorithm of GlycoPep Grader 
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could henceforth be used to improve any other algorithm that assigns glycopeptides based on 
their MS/MS data. 
4.1 Introduction 
 Glycopeptide analysis is an important approach for protein glycosylation profiling 
because it provides glycosylation site-specific information.
1,2
 However, glycopeptide analysis 
using MS/MS data is challenging, even after the recent emergence of numerous automated tools 
that facilitate the process. Several bioinformatics tools have been developed to interpret 
glycopeptide MS/MS data generated by different fragmentation techniques, including electron 
transfer dissociation (ETD), higher-energy collisional dissociation (HCD), and collision induced 
dissociation (CID), the most common fragmentation technique used for glycopeptide analysis.
3-5
 







 the latter being the focus of this study. Although these tools greatly 
enhance data analysis speed and reduce turn-around time for protein glycosylation profiling, 
automated glycopeptide analysis could have some drawbacks. For example, an assessment of the 
accuracy of GlycoPep Grader in Chapter 3 of this dissertation revealed that it has some limitation 
in scoring CID spectra from fucosylated glycopeptides, and this weakness could be detrimental 
in estimating fucosylation in glycoproteins.    
Accurate determination of the fucosylation levels of glycoproteins is vital in 
understanding some critical biological activities of glycoproteins because the degree of 
fucosylation can affect the bioactivity of some glycoproteins. For example, an increase in 
antibody fucosylation can lead to decreased antibody dependent cellular cytotoxicity (ADCC).
9-
11
 Glycopeptides can be fucosylated at two main sites on the glycan components: (1) core 
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fucosylation, where a fucose residue is appended to a GlcNAc residue on the pentasaccharide 
core of a glycan moiety; and (2) antenna fucosylation where the fucose residue is attached to a 
GlcNAc residue on one of the glycan’s antennae.
12
  While antenna fucosylation is rare, core 
fucosylation is very common, and it is the focus of this study. Although core- and antenna- 
fucosylated glycopeptide isomers can be distinguished using MS/MS data,
12
 a thorough analysis 
of the fragmentation patterns of fucosylated glycopeptides is still lacking in the literature, 
making it difficult to write accurate rules for scoring CID spectra from fucosylated 
glycopeptides.  
The development of efficient automated glycopeptide scoring algorithms depends on the 
comprehensive analysis and identification of the characteristic fragmentation patterns of 
glycopeptides containing varying glycan components. Hence, writing accurate glycopeptide 
scoring algorithms is, perhaps, the most challenging part of software development due to the 
micro heterogeneity of N-linked glycans, since the scoring rules must be specific for each glycan 
type, and they must be based on the predominant product ions of glycopeptide type upon 
fragmentation.
8
 Currently, very limited information is available on the fragmentation behavior of 
fucosylated glycopeptides because fucose is generally considered to be a very labile 
monosaccharide.
13
 This limitation in the understanding of the characteristic fragmentation 
behavior of fucosylated glycopeptides could translate into weaknesses in glycopeptide tools, as is 
the case with GlycoPep Grader.  Hence, a thorough study of the characteristic behavior of 
fucosylated glycopeptides upon CID fragmentation can uncover prominent product ions that 
could be used for accurate assignment of fucosylated glycopeptides to MS/MS data.    
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Herein, we use a large dataset containing CID spectra of glycopeptides from well 
characterized glycoproteins to study the fragmentation characteristics of fucosylated 
glycopeptides. The overall goal of this study is to identify the source of GlycoPep Grader’s 
limitation in scoring fucosylated glycopeptides, and to suggest possible changes to improve the 
software. The results of our study show that although the fucose residue is labile, the core fucose 
does not always dissociate from the glycan during CID fragmentation. In addition to the 
fragmentation pathway where the fucose residue dissociates from the precursor glycopeptide ion, 
we identified an additional fragmentation pathway, where the fucose residue remains attached to 
the glycan core. A study of the current GlycoPep Grader scoring rules indicate that the software 
does not take this additional fragmentation pathway into consideration when scoring fucosylated 
glycopeptides. Based on this finding, we propose new scoring rules for fucosylated 
glycopeptides which could be incorporated into GlycoPep Grader, and any other algorithm that 
scores CID spectra of glycopeptides, in order to address its limitations reported in Chapter 3 of 
this dissertation.   
4.2 Experimental   
 The CID data used in this study are the same data used in Chapter 3 of this dissertation. 
Hence, details regarding the materials and reagents, sample preparation, LC-MS/MS analysis, 
and generation of the CID dataset are found in the experimental section (Section 3.2) of Chapter 
3.   
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4.3 Results and Discussion  
4.3.1 Overview of GlycoPep Grader’s Scoring Algorithm 
In order to identify and correct GlycoPep Grader’s weakness in scoring fucosylated 
glycopeptides, it is important to understand the overall scoring rules of the software. The detailed 
scoring algorithm has been reported by Woodin et al.
8
  A brief summary of the scoring algorithm 
is discussed herein. GlycoPep Grader scores potential glycopeptide candidate compositions 
(including decoy glycopeptides) by searching predicted in-silico product ions of the glycopeptide 
compositions against the experimental CID data. The candidate that best matches the 
experimental spectrum (candidate with highest score) is assigned to the CID spectrum being 
studied. The software scores candidate glycopeptide compositions using two predominant types 
of product ions that have been shown to be present in CID spectra of glycopeptides: the peptide 
plus pentasaccharide core ions, referred to as [peptide + core component] product ions; and 
product ions resulting from step-wise neutral losses of terminal monosaccharide residues from 
the precursor glycopeptide composition, referred to as [precursor – monosaccharide] product 
ions.  The numbers of predicted peptide and glycan ions matched to the experimental spectra are 
used to calculate the PeptideScore and the GlycanScore, respectively, and both scores are used to 
calculate the overall score (GlycopeptideScore) of the glycopeptide candidate. The [peptide + 
core component] and [precursor – monosaccharide] product ions that are searched by the current 
version of GlycoPep Grader when scoring glycopeptide compositions are shown in Figure 1.  
To compute the PeptideScore, the software searches for six possible product ions at 
different charge states. These include: (1) the [naked peptide], (2) [peptide + HexNAc], (3) 
[peptide + 2HexNAc], (4) [peptide + 2HexNAc + Hex], (5) [peptide + 2HexNAc + 2Hex], and 
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(6) [peptide + 2HexNAc + 3Hex]. For the GlycanScore, the [precursor – monosaccharide] ions 
searched by GlycoPep Grader depend on the type of glycan component of the glycopeptide 
candidate. The glycan types are divided into 8 categories: (1) Non-fucosylated high mannose 
type glycans; (2) fucosylated high mannose type glycans; (3) Non-fucosylated complex or hybrid 
type glycans containing sialic acid; (4) fucosylated complex or hybrid type glycans containing 
sialic acid; (5) fucosylated complex or hybrid type glycans that do not contain sialic acid and 
have more HexNAc than Hex residues; (6) fucosylated complex or hybrid type glycans that do 
not contain sialic acid and have more Hex than HexNAc residues; (7) complex or hybrid type 
glycan structures with a greater number of HexNAc than Hex residues and do not contain fucose 
or sialic acid residues; and (8) complex or hybrid type glycans that have more Hex than HexNAc 






Figure 1. Representation of the predominant product ions searched by GlycoPep Grader when scoring N-
linked glycopeptide compositions against CID spectra. Six possible [peptide + core component] ions (A) 
are searched for as well as several [precursor-monosaccharide] ions (B) for each of the eight groups (see 
text) of glycopeptides.  The monosaccharide neutral losses evaluated for group 1 (see text) are shown in 
the purple oval. For group 2, the relevant losses are shown in both the purple oval and the yellow circle. 
For group 3, the relevant losses are shown in the blue oval. For group 4, they are shown in the blue oval 
and yellow circle. For group 5, they are shown in the orange oval and yellow circle. For group 6, they are 
shown in the green oval and yellow circle. For groups 7 and 8, neutral losses are in the orange oval at 
bottom left, and by the green oval at bottom right, respectively. This figure is reprinted with permission 
from Reference 8.   
 
The rest of this chapter describes how the scoring rules summarized above and the 
analysis of the fragmentation patterns of CID spectra were used to identify the source of 
GlycoPep Grader’s limitation in scoring spectra from fucosylated glycopeptides.  
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4.3.2 Evaluation of the Peptide and Glycan Scores of High-mannose, Non-fucosylated, and 
Fucosylated Glycopeptide Compositions  
Since the GlycopeptideScore of any glycopeptide candidate is based on the peptide and 
glycan scores of the glycopeptide composition, we studied the PeptideScores and the 
GlycanScores for the 100 target glycopeptide compositions that were generated and scored 
against their known CID spectra in Chapter 3 of this dissertation. The goal of this particular 
study was to find out whether GlycoPep Grader’s weakness in scoring fucosylated glycopeptides 
results from the peptide or glycan scoring rules, or both. The glycan and peptide scores can range 
from zero to one; hence, for each of the three glycopeptide categories (high mannose, non-
fucosylated hybrid/complex, and fucosylated hybrid/complex glycopeptide compositions), the 
peptide and glycan scores were divided into three scoring groups: (1) glycopeptides with a 
peptide or glycan score of zero, (2) glycopeptides with peptide or glycan scores greater than zero 
but less than 0.5, and (3) candidates with scores between 0.5 and one. For each of the three 
glycopeptide categories, the number of glycopeptide compositions with scores in each of the 
three scoring groups were expressed as a percentage of the total number of glycopeptide 
candidates in that category.  Note, while the focus of this study is on the fucosylated 
glycopeptides, the scores of both fucosylated and non-fucosylated glycopeptides were 
interrogated, so that we could compare the scores for the fucosylated species to the scores of 
glycopeptides that are typically scored correctly, even against 20 decoys.  
The results of the analyses of the peptide and glycan scores of the 100 spectra are 
summarized in Figure 2. As shown in Figure 2A, 100 % (33 out of 33) of the high mannose 
glycopeptides, 64% (21 out of 33) of the non-fucosylated glycopeptides, and 97% (33 out of 34) 
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of fucosylated glycopeptides had PeptideScores between 0.5 and 1. None of the glycopeptide 
compositions had a PeptideScore of zero. However, 36% of non-fucosylated H/C glycopeptides 
had a score greater than zero but less than 0.5, while only 3% of fucosylated glycopeptides had a 




Figure 2. Bar graphs showing results of the evaluation of the peptide (A) and glycan (B) scores of high-
mannose, non-fucosylated hybrid/complex (H/C), and fucosylated hybrid/complex type glycopeptide 
compositions. A high percentage of high-mannose and non-fucosylated hybrid/complex type 
glycopeptides had peptide and glycan scores between 0.5 and 1; and none of them had a peptide or glycan 
score of zero. On the contrary, a high percentage (97%) of fucosylated hybrid/complex type glycopeptides 
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had PeptideScores between 0.5 and 1 but up to 26.5% had glycan scores of zero (purple box) and only 
47% had glycan scores between 0.5 and 1(purple box). 
 
For the GlycanScores, (Figure 2B), 94 % of the high mannose glycopeptides and 88% of the 
non-fucosylated glycopeptides had a glycan score between 0.5 and 1; while only 47% of 
fucosylated glycopeptides had a GlycanScores between in the same range.  Neither the high 
mannose nor non-fucosylated H/C glycopeptides had a GlycanScore of zero. However, up to 
27% of the fucosylated glycopeptides had a GlycanScore of zero and 27% had GlycanScores 
between 0 and 0.5.     
These results were used to evaluate GlycoPep Grader’s peptide and glycan scoring rules. 
A high number of high-mannose and non-fucosylated hybrid/complex glycopeptide 
compositions that had peptide and glycan scores greater than 0.5; these species are typically 
correctly assigned. By comparison, many (97%) of the fucosylated hybrid/complex glycopeptide 
compositions had PeptideScores of 0.5 or higher, but up to 26% had a GlycanScore of zero, and 
a total of 53% had GlycanScores of less than 0.5, indicating the peptide scoring rules for 
fucosylated glycopeptides are well written, while there are some short-comings with the glycan 
scoring rules. Hence, GlycoPep Grader’s weakness in scoring fucosylated glycopeptide 
composition, as identified in Chapter 3 of this dissertation, can be ameliorated by improving the 
scoring rules for the [precursor – monosaccharide] product ions from fucosylated glycopeptide 
compositions.   
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4.3.3 CID Fragmentation Characteristics of N-linked Glycopeptides 
 After analyzing the peptide and glycan scores, we studied the CID fragmentation patterns 
and the scoring rules for high-mannose and non-fucosylated hybrid/complex glycopeptide 
compositions, which are accurately scored by GlycoPep Grader, and compared them to those of 
fucosylated glycopeptide compositions. The aim was to verify if the scoring rules correlate to the 
characteristic product ions of each of the glycopeptide types upon CID fragmentation.  
 4.3.3.1 Fragmentation Characteristics of High-mannose and Non-fucosylated 
Complex/hybrid Glycopeptide Compositions 
 Figure 3 shows example CID spectra that exhibit the characteristic fragmentation patterns 
of high-mannose and non-fucosylated hybrid/complex type glycopeptide compositions. CID 
fragmentation of high-mannose type glycopeptides were characterized by neutral losses of Hex 
residues from the precursor glycopeptide ion (Figure 3A), while the fragmentation of non-
fucosylated hybrid/complex type glycopeptides were characterized by neutral losses of Hex and 
HexNAc residues from the precursor ion (Figure 3B). No alternative fragmentation pathways 
were identified. Both spectra contain the [peptide + core component] (peaks with black star) and 
the [precursor – monosaccharide] product ions (peaks with red star) which are used by GlycoPep 
Grader to score glycopeptide compositions. The [peptide + core component] ions were present in 
both the charge state of the precursor glycopeptide and at lower charge states, while the 
[precursor – monosaccharide] product ions were mainly present at the charge state of the 
precursor ion.  
After studying the CID spectra and confirming the characteristic product ions, we investigated 
whether or not GlycoPep Grader’s scoring algorithm is designed to search for the characteristic 
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product ions in the CID spectra of high-mannose and non-fucosylated hybrid/complex type 
glycopeptides. When calculating the PeptideScores for both types of glycopeptide compositions, 
GlycoPep Grader searches for the six possible [peptide + core component] product ions at both 
the charge state of the precursor ion and at decremented charge states. 
 
Figure 3. CID spectra of a high-mannose glycopeptide from RNase B (A) and a non-fucosylated hybrid 
type glycopeptide from HIV-1 envelope glycoprotein, C.97ZA012 gp140 (B). The spectra show the 
characteristic fragmentation patterns of high-mannose and non-fucosylated H/C type glycopeptides. High-
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mannose spectra (A) are characterized by neutral losses of Hex residues from the precursor ion (black 
oval) and spectra of non-fucosylated H/C type glycopeptides (B) are characterized by neutral losses of 
Hex and HexNAc residues from the precursor ion (black oval). Both spectra contain [peptide + core 
component] ions (black stars) and [precursor – monosaccharide] product ions (red stars) which are used 
by GlycoPep Grader to score N-linked glycopeptides. Different oxonium ions (orange stars) are also 
observed, and no alternative fragmentation pathway was identified.   
 
For the GlycanScores, the software searches for the predominant production ions resulting from 
the neutral losses of Hex residues (for high-mannose glycopeptides) and Hex and HexNAc 
residues (for non-fucosylated glycopeptides) from the glycopeptide precursor ions. Overall, our 
study of GlycoPep Grader’s scoring algorithm for high-mannose and non-fucosylated 
glycopeptides indicates that the rules are well written, since the software searches for the product 
ions which are typically present in the CID spectra from these types of glycopeptide 
compositions. The well-written rules correlate with the high numbers of high-mannose and non-
fucosylated glycopeptides that out-scored decoy glycopeptides when GlycoPep Grader’s scoring 
algorithm was assessed in Chapter 3 of this dissertation.  
We next studied the CID spectra and GlycoPep Grader’s scoring rules for fucosylated 
glycopeptide compositions to investigate if the same correlation exists between the characteristic 
product ions in spectra of fucosylated glycopeptides and their scoring rules.   
4.3.3.2 Fragmentation Characteristics of Fucosylated Glycopeptides 
For a thorough study of the fragmentation patterns of core-fucosylated glycopeptides 
under CID conditions, two sets of model fucosylated glycopeptides from well characterized 
proteins were used. These include fucosylated glycopeptides that contain sialic acid and 
fucosylated glycopeptide compositions that do not contain sialic acid. After extensive analysis of 
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CID data from these model glycopeptide compositions, we identified two characteristic 
fragmentation pathways. One pathway results in product ions without appended fucose while the 
other generates product ions containing the core fucose residue.    
A representative CID spectrum of a fucosylated glycopeptide containing sialic acid that 
exhibits both fragmentation pathways is shown in Figure 4. Figure 4A shows the fragmentation 
pathway that occurs when the labile sialic acid and fucose residues dissociate from the glycan 
component. The predominant [precursor-monosaccharide] product ion (e.g peak at m/z 1486.4) 
resulted from the neutral loss of sialic acid from the glycopeptide precursor ion (black oval) and 
subsequent neutral loss of the fucose residue, followed by neutral losses of Hex and HexNAc 
residues from the glycan’s antennae led to several [precursor – monosaccharide] product ions 
(peaks indicated with red star) and [peptide + core component] product ions (peaks indicated 
with black star) that do not contain the fucose residue. The most abundant ion that does not 
contain fucose residue was the Y1 ion (e.g peak at m/z 1364.8) at a charge state lower than that 
of the precursor ion.  
Figure 4B shows the second fragmentation pathway, during which the sialic acid residue 
dissociates from the glycan component, but the core-fucose residue does not. The predominant 
[precursor-monosaccharide] product ion (peak at m/z 1486.4) also resulted from the loss of sialic 
acid from the glycopeptide precursor ion (black oval), and the subsequent step-wise neutral 
losses of monosaccharide residues from the glycan’s antennae, without loss of fucose, led to 
product ions that have the appended core fucose residue. The most abundant ion that contains the 
appended fucose residue was the Y1+Fuc ion (e.g peak at m/z 1510.9) at a charge state lower 
than that of the precursor ion.  
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For both fragmentation pathways, the [precursor – monosaccharide] product ions were 
observed only at the charge state of the precursor glycopeptide while the [peptide + core 
component] product were observed at both the charge state of the precursor and the next lower 
charge state. The characteristic oxonium ion for sialylated glycopeptides at m/z 657
14,15
 was also 





Figure 4. Representative CID spectra of a fucosylated complex type glycopeptide containing sialic acid 
showing two fragmentation pathways observed for fucosylated glycopeptides. (A) shows the 
fragmentation path that leads to [precursor – monosaccharide] product ions (red star) and [peptide + core 
component] product ions (black star) that do not contain the core fucose. (B) shows the fragmentation 
pathway that generates [peptide + core component] product ions (black star) and [precursor – 
monosaccharide] product ions (red star) that contain the appended core fucose. Oxonium ions (orange 
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star) are also observed. Ions generated by each fragmentation pathway are annotated and shown in black 
while non-related peaks are shown in gray. Precursor ions are in black ovals. 
 
 Analysis of CID data from fucosylated glycopeptides that do not contain sialic acid also 





Figure 5. Representative CID spectra of a fucosylated complex type glycopeptide that does not contain 
sialic acid showing two fragmentation pathways observed for fucosylated glycopeptides. (A) shows the 
fragmentation path that leads to [precursor – monosaccharide] product ions (red star) and [peptide + core 
component] product ions (black star) that do not contain the core fucose. (B) shows the fragmentation 
pathway that generates [peptide + core component] product ions (black star) and [precursor – 
monosaccharide] product ions (red star) that contain the appended core fucose. Oxonium ions (orange 
star) are also observed. Ions generated by each fragmentation pathway are annotated and shown in black 
while non-related peaks are shown in gray. Precursor ions are in black ovals. 
 
The characteristic [peptide + core component] and [precursor – monosaccharide] product ions 
from the two pathways were identified irrespective of the charge state of the precursor 
glycopeptide and the relative numbers of Hex and HexNAc residues of the glycan component. 
After identifying the two common CID fragmentation pathways for fucosylated 
glycopeptides, we studied GlycoPep Grader’s scoring rules to verify whether or not the software 
searches for the characteristic product ions (ions with and without appended fucose) generated 
by the two pathways when scoring CID data from fucosylated glycopeptide compositions. We 
noticed that the current version of GlycoPep Grader searches for product ions resulting from only 
one of the two possible fragmentation pathways: the product ions that do not contain appended 
fucose. Based on this finding, we propose that the algorithm be redesigned to search for 
additional product ions (product ions that contain the appended core fucose residue) to increase 
the scores of fucosylated glycopeptides compositions.  The proposed ions are shown in Figure 6. 
The product ions (and one oxonium ion at m/z 366) that are searched for by the current version of 
GlycoPep Grader are shown in Figure 6A. Figure 6B includes the proposed product ions that 
contain core-fucose (ions indicated by red asterisks) that should also be searched for when 
scoring CID data of fucosylated glycopeptides.  In addition, we also propose that the search 
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includes additional oxonium ions, as shown in the figure. The explanations for including the new 















Figure 6. Schematic representation of the current product ions used by GlycoPep Grader to score N-
linked glycopeptides (A) and proposed product ions for future GlycoPep Grader scoring (B).  The 
proposed product ions include ions containing appended fucose (ions with red asterisks), for the scoring 
of fucosylated glycopeptides. Prominent oxonium ions common in CID spectra of N-linked glycopeptides 
are also included. The color codes of the [precursor – monosaccharide] ions are explained in Figure 1. 
This figure is adapted from Reference 8.   
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4.4 GlycoPep Grader Updates 
To determine whether the scores of fucosylated glycopeptides would increase by scoring 
product ions with appended fucose, we tested a rule that scores the [peptide + component] 
product ions containing fucose residues. For any fucosylated candidate glycopeptide, the 
software searched for [peptide + component] ions with or without appended fucose in them and 
gave credit for a correct assignment if either set of ions was identified.  Representative results 
from the addition of this rule are shown in Table 1. The PeptideScores (highlighted in green) of 
some fucosylated glycopeptide candidates (targets1 and 2, and some decoys of target number 3) 
increased slightly, and this increase led to higher GlycopeptideScores (also highlighted in green). 
As shown in Table 1, the new rule helped to increase the scores of a few fucosylated 
glycopeptide candidates (both targets and decoys) but not most of them. This outcome was 
expected since our analysis of the peptide and glycan scores (shown in Figure 2) indicated that 
the glycan rules were more of a problem.   
The new rules we proposed for scoring the [precursor – monosaccharide] product ions 
containing appended fucose, have not yet been implemented into the scoring algorithm, so this 
aspect of the work is ongoing. Yet, some scores in Table 1 indicate that the GlycanScores of 
fucosylated glycopeptide candidates can be increased drastically if the same rules for scoring 
non-fucosylated hybrid/complex glycopeptides are implemented for scoring fucosylated 
glycopeptides but with the addition of fucose residues to the product ions that are being searched 
for. For example, the glycan components of target 1 (glycan: [Hex]4[HexNAc]3[Fuc]1) and its 
decoy (glycan: [Hex]4[HexNAc]3) only differ by a fucose residue, but the non-fucosylated 
decoy has a GlycanScore of 1 (the highest possible glycan score for any glycopeptide) while the 
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target has a GlycanScore of zero. A similar phenomenon is observed for target number 3 and its 
first decoy. Hence, the GlycanScores of fucosylated glycopeptides can be drastically increased if 
the same rules for scoring non-fucosylated hybrid/complex glycopeptides are implemented but 
with the addition of fucose residues to the [precursor – monosaccharide] product ions that are 
scored.  
Table 1. Example of glycopeptide candidate scores before and after addition of a new rule that searches 
for [Peptide + core component] ions with and without fucose. 
 
Scores that improved due to the addition of the new rule are highlighted in green. GlycanScores that 
signal how the glycan scoring rules could be modified are highlighted in yellow. 
 
4.4.1 Other Potential Areas for Improving GlycoPep Grader Scoring 
After extensive study of GlycoPep Grader’s scoring algorithm, we found additional areas 
where some changes can be made in order to improve the glycopeptide candidate scores, 
including those of fucosylated glycopeptides. First, the intensity threshold limit for scoring 
Old New Old New Old New
Target SNITGLLLVR 21 / 22 = 0.95 22 / 22 = 1 [Hex]4[HexNAc]3[Fuc]1 0 / 16 = 0 0 / 16 = 0 63.95 67.00
Decoy 1212.66414 15 / 20 = 0.75 15 / 20 = 0.75 [Hex]4[HexNAc]3 8 / 8 = 1 8 / 8 = 1 83.25 83.25
Target EEQFNSTFR 16 / 20 = 0.8 17 / 20 = 0.85 [Hex]5[HexNAc]4[NeuNAc]1[Fuc]1 0 / 12 = 0 0 / 12 = 0 53.6 56.95
Decoy 1284.5635 13 / 18 = 0.72 13 / 18 = 0.72 [Hex]5[HexNAc]4[NeuNAc]1 4 / 8 = 0.5 4 / 8 = 0.5 64.89 64.89
Target EEQYNSTYR 17 / 18 = 0.94 17 / 18 = 0.94 [Hex]3[HexNAc]5[Fuc]1 6 / 10 = 0.6 6 / 10 = 0.6 83.08 83.08
Decoy 1316.56284 12 / 16 = 0.75 12 / 16 = 0.75 [Hex]3[HexNAc]5 6 / 6 = 1 6 / 6 = 1 83.25 83.25
Decoy 1941.75504 2 / 6 = 0.33 3 / 6 = 0.5 [Hex]2[HexNAc]2[Fuc]1 0 / 8 = 0 0 / 8 = 0 22.33 33.50
Decoy 643.26394 3 / 21 = 0.14 5 / 21 = 0.24 [Hex]5[HexNAc]6[Fuc]1 6 / 10 = 0.6 6 / 10 = 0.6 29.37 35.75








product ions resulting from the cleavage of fucose and sialic acid residues is typically about three 
times higher than the intensity threshold for scoring the predominant product ions from non-
fucosylated or sialylated glycopeptides. For example, at a normalization level of 2%, the 
intensity threshold limit for the predominant product ions from high-mannose and non-
fucosylated glycopeptides is 3% while those from fucosylated glycopeptides is 10%. These 
levels were set on the basis that the fucose residue is very labile and product ions resulting from 
neutral loss of this residue would be very intense. However, we found that this is not always the 
case, as some spectra of fucosylated glycopeptides did not contain very intense [precursor – 
monosaccharide] product ions resulting from the loss of fucose from the precursor glycopeptide, 
and a few spectra completely lacked the ion. Hence, we propose that instead of using product 
ions resulting from the loss of fucose from the precursor glycopeptide ion as the predominant 
product ions for fucosylated glycopeptides, the Y1+Fuc ion should be used. This ion was present 
in all CID data of fucosylated glycopeptides and was the most intense ion containing fucose in 
some cases (e.g peak at m/z 1510.9 in Figure 4). In addition, we propose that the threshold limits 
for scoring product ions from fucosylated glycopeptide compositions should be the same as those 
from high-mannose and non-fucosylated hybrid/complex glycopeptide compositions.   
Alternatively, a noise correction approach that prevents the use of different intensity 
threshold values for scoring different types of glycopeptides could be incorporated into 
GlycoPep Grader. CID data could be binned into 100 Da bins, and only the top 5 ions in each bin 
should be used for scoring glycopeptide candidates; we have shown previously that this approach 
is effective for scoring glycopeptides’ ETD spectra.
16
 In addition, the scoring algorithm could be 
changed so that the most intense peaks (e.g the top 10 most intense peaks) of each spectrum get 
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more weight, thus automatically penalizing any candidate for which all or some of the most 
intense peaks are not matched.   
Another area where GlycoPep Grader can be improved is by increasing the scores of 
precursor ions at charge states of 3+ or higher. We found that although several precursor ions at a 
charge state greater than two out-score their decoys, the candidate scores are typically less than 
45% while the scores of glycopeptides at charge state of two are mostly greater than 70%. Future 
updates to increase the score gap between decoy glycopeptides and target candidates at high 
charge states would greatly improve the scoring algorithm.   
Finally, glycopeptide scores could also be increased if the scoring rules are modified so 
that the algorithm searches for more oxonium ions, as shown in Figure 6B. CID fragmentation of 
N-linked glycopeptides typically results in oxonium ions at m/z 366, 528, and 690
17,18
 (see 
figures 4 and 5), and the spectra from glycopeptide compositions containing sialic acid have an 
additional oxonium ion at m/z 657
14,15
 (see Figure 4). The current version of GlycoPep Grader 
only searches for the oxonium ion at m/z 366. This ion may be out of range for some data 
generated on ion trap instruments because the lowest mass range on these instruments is typically 
1/3 the m/z value of the precursor ion.
19
 Hence, instead of scoring only the oxonium ion at m/z 
366, a new rule could be included to score the oxonium ion at m/z 657 (for sialylated 
glycopeptides only), and the ions at either m/z 366, or 528, or 690 (for all types of glycopeptide 




The development of bioinformatics tools for the interpretation of glycopeptide MS/MS 
data is an emerging and challenging field. As more knowledge is being gained on the 
fragmentation behaviors of different types of glycopeptides of varying peptide lengths, and at 
different charge states, high quality software will be developed and more updates will be seen in 
the near future on the existing glycopeptide scoring algorithms to improve their glycopeptide 
scores.   
In Chapter 3 of this dissertation, we showed that GlycoPep Grader has unprecedented 
strengths in scoring CID data from high-mannose and non-fucosylated hybrid/complex 
glycopeptide compositions, but the software does not effectively score spectra from fucosylated 
glycopeptide compositions. After extensive studies of GlycoPep Grader’s scoring algorithm and 
the fragmentation characteristics of CID data from high-mannose, non-fucosylated 
hybrid/complex, and fucosylated hybrid/complex glycopeptide compositions, we identified an 
alternative fragmentation pathway for fucosylated glycopeptides that was not incorporated in 
GlycoPep Grader’s scoring rules. The alternative fragmentation pathway leads to [Peptide + core 
component] and [precursor – monosaccharide] product ions that contain appended fucose 
residue. A test of a new GlycoPep Grader rule fore scoring [Peptide + core component] product 
ions containing fucose residues showed progress in improving the scores of fucosylated 
glycopeptides. The incorporation of the proposed rules for scoring [precursor – monosaccharide] 
product ions that contain appended fucose residue, and implementation of the additional 
proposed updates described in Section 4.4.1, should drastically improve the scores of fucosylated 
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glycopeptides and lead to no or few decoys out-scoring fucosylated glycopeptide target 
candidates.   
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Chapter 5: Conclusion 
 
5.1 Dissertation Summary 
The work reported in this dissertation focused on disulfide bond characterization in IgG3 
antibodies using tandem mass spectrometry and the development of a tool that assess the quality 
of algorithms that assign glycopeptides to tandem mass spectrometry data. Disulfide bonds and 
N-linked glycosylation are two important protein post-translational modifications (PTMs) that 
are common in proteins, and they play a vital role in maintaining protein stability, structure, and 
function.
1-4
 As proteins are increasingly used for the development of biotherapeutics and as 
biomarkers for diseases, there is an accompanying need for thorough characterization of 
disulfide bonds and glycosylation, as well as other PTMs, in order to ensure the desired 
structural and biological properties of protein drugs and for proper identification of disease 
biomarkers. Tandem mass spectrometry is an invaluable tool for the characterization of these 
PTMs and for protein characterization in general.   
High resolution mass spectrometry was used to study the disulfide connectivity of 
endogenous IgG3 antibodies to investigate whether or not they contain disulfide-mediated 
isoforms. Among the four classes of IgG’s (IgG1, IgG2, IgG3, and IgG4), disulfide-based 
isomers have been identified for endogenous IgG2 and IgG4.
5-7
 No disulfide isomers have been 
reported for endogenous IgG1, although low amounts of IgG1 disulfide isomers have been 
reported during drug development from recombinant IgG1.
8
 Disulfide mediated isomers have not 
been studied for endogenous IgG3 due to its short half-life in serum, which made it not suitable 
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for drug development. However, IgG3 is now a viable drug candidate due to recent reports that 
show that the half-life of IgG3 can be extended by point mutation of amino acids in the CH3 
domain.
9
 This finding creates an urgent need for thorough characterization of the structural 
properties of IgG3 antibodies, such as its disulfide bond connectivity.  By using electron transfer 
dissociation and collision induced dissociation, the native disulfide bond connectivity in the 
constant region of IgG3 was confirmed, but no alternative disulfide connectivity was identified, 
indicating that no disulfide isoforms are present in the constant region of endogenous IgG3.
10
 
Hence, alternative disulfide bonds should not be present in recombinant IgG3 molecules. This 
study provides the first benchmark for disulfide bond analysis in IgG3 using high resolution 
mass spectrometry.  
Protein glycopeptide analysis is a challenging task due to the microheterogeneity of 
glycans. Several glycans can occupy the same different glycosylation site, making manual 
glycopeptide analysis from MS/MS data extremely challenging. As a result, numerous automated 
tools have emerged in recent years to facilitate glycopeptide analysis from MS/MS data.
11-13
 This 
increase in the glycopeptide tools raises the need for a simple method to assess the quality of the 
tools in order to increase confidence in their results. However, there is no consensus in the 
proteomics field regarding the best method to assess an automated glycoproteomics tool. Two 
new tools, a Glycopeptide Decoy Generator, and a large dataset of manually assigned CID 
spectra from diverse glycopeptide compositions are reported in this dissertation. These tools 
enable end-users of glycoproteomics tools to rapidly assess the quality of any algorithm that 
assigns glycopeptides to CID data.
14
 The tools can also be used by software developers to 
develop high quality scoring algorithms. The importance of the new tools was demonstrated by 
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using them to assess the quality of an existing software, GlycoPep Grader; a tool that assigns 
glycopeptide’s CID data. We found that GlycoPep Grader has some weaknesses in scoring 
spectra from fucosylated glycopeptides.  Finally, in Chapter 4, we investigated the source of the 
weaknesses in GlycoPep Grader and proposed new rules to improve its scoring algorithm. 
Overall, the work reported in this dissertation presence a benchmark for future disulfide 
bond analysis in IgG3 antibodies,
10
 and it introduces new tools that enable efficient glycopeptide 
software development and rapid evaluation of existing glycopeptide tools,
14
 as well as a 
systematic approach to pin-point sources of flaws in glycopeptide scoring algorithms.    
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